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After a period of successful control, pertussis or whooping cough has, in the past decade, 
had large nationwide epidemics with a new adolescent risk-group. The surveillance 
confirmation criteria for pertussis included DNA testing by polymerase chain reaction 
(PCR) beginning in 1997, which is more sensitive than the culture gold-standard 
laboratory test, especially in adolescents and adults. This dissertation uses surveillance 
date from the state of Michigan to retrospectively assess the internal validity of reported 
pertussis surveillance cases. Data from the United States Centers for Disease Control and 
Prevention evaluated characteristics predictive of high incidence counties.  
Michigan pertussis records (2000 - 2010) were evaluated according to the clinical case 
definition; a third included positive PCR results. Confirmed and probable cases 
comprised 69.4% of the data, and another 14% could have been confirmed had an 
adequate cough length been reported.  An odds of insufficient cough duration was 
reported among PCR positive cases, 2.9 (95% CI: 1.57 - 2.79) times greater than in those 
without PCR positive results. Similar findings were observed for cases confirmed by 
culture and epidemiologic linkage. These findings show confirmatory criteria are 
frequently given precedence over the clinical case definition. We recommend that the 
case definition be more internally consistent with regard to the role of positive laboratory 
results. This dissertation illustrates that the current pertussis surveillance case definition 
has high internal validity. Surveillance cases need to be held to more stringent criteria for 
verification than for medical diagnosis, since it is the basis for allocation of time and 
resources for case and outbreak investigation.  
County-level regression analysis of socio-structural risk-factors in national United States 
pertussis data (1990 - 2008), indicated that denser counties with a higher prevalence of 
healthcare barriers and poor child health were associated with decreased pertussis 
incidence. We observed an element of disease risk associated with county-level factors. 
Our findings could be explained either by low rates of disease or a less developed 
xi 
 
surveillance structure. Further research to identify the county elements driving the risk 




Chapter 1  
Background of Pertussis Surveillance and Control in the United States 
1.1. Introduction 
Pertussis, commonly referred to as whooping cough, is one of the traditional childhood 
diseases preventable by vaccination. The illness was first described by Guillaume de 
Baillou, in 1578, as a highly fatal fever primarily affecting infants between four and ten 
months of age, producing severe bursts of coughing every four to five hours.
1
 The 
causative bacterium, Bordetella pertussis, was first identified by Bordet and Genou in 
1906.
2
 The initial attempts at making vaccines had inconsistent results until Danish 
researchers in the late 1920s used whole, killed B. pertussis bacteria in the innoculum.
3
 
Large scale field trials were run between 1946 and 1948, and found that while there was a 
range of vaccine efficacy (61- 89%) the vaccine conferred considerable protection, with an 
estimated protective risk ratio of 0.22(0.18-.26).
3
 The subsequent nationwide vaccination 
programs in United States were very effective in reducing the annual number of cases to 
less than 5,000 annually between 1968 and 1992.
4
 Since routine vaccination began, 
mortality nationwide has declined dramatically and still remains well below pre-
vaccination levels, with less than 50 annual pertussis-related deaths since 1966.
4
  
The past twenty years have seen a resurgence of pertussis, resulting in endemic 
transmission with cyclic epidemics. The changing perception of the importance of 
pertussis is most clearly illustrated in the development of the pertussis objectives of the 
United States’ Healthy People goals. These objectives, developed by the Centers for 
Disease Control and Prevention (CDC) and overseen by the Public Health Service, 
provide quantitative health objectives with ten year targets to improve the health of all 
people in the United States.
5
 These goals are divided into topical areas, including an 
immunization and infectious diseases portion that specifies targets for both pertussis 
disease reduction and immunization coverage.
5-7
 The original Healthy People 2000 goals 
for pertussis, established in 1988 when there were 3,450 annual cases, ambitiously 
targeted a low of 1,000 cases nationwide.
5





disease reduction goals for Healthy People 2010 narrowed in scope, focusing on children 
less than 7 years of age, in whom there were 3,417 cases, and revised a 2010 target of 
fewer than 2,000 cases.
6
 However, the incidence of pertussis continued to rise during the 
first decade of the 21
st




When creating the current 2020 infectious disease goals, pertussis control was 
operationalized in two high-risk populations, infants (< 1 year) with a target of less than 
2,500 annual confirmed cases and adolescents (11 - 18 years) with less than 2,000 
confirmed cases.
7
  The current disease reporting based on a 4-year average from 2006-
2010, shows just over 2,700 cases in infants and 3,300 cases in adolescents.
7
  
The recalibration of these disease reduction goals illustrates the adjustment to the 
changing epidemiology of pertussis throughout the period from 1988 to the present. First, 
it recognizes that the number of pertussis cases continually increased well beyond the 
incidence goals that had been set. Secondly, it highlights the emergence of a new risk 
group, adolescents. Thirdly, the reclassification of the primary target population from the 
entire population to infants reflects that fact that greater incidence and severity of infection 
chiefly occur among the very young. The current 2020 infant target of less than 2,500 
confirmed cases (62.5 cases /100,000 infants) is not necessarily a marker of disease 
reduction, but rather an acceptance of the difficulties of disease control, as the 2008 
baseline was 2,777 reported infant cases. These changes reflect an unprecedented 
resurgence of pertussis, with a slightly older epidemiologic profile, having increased 
incidence among those 11-18 years old, and to a lesser extent adults.
8
 This increase 
occurred most clearly during the 1990s but the foundational increase in cases can be traced 
back to the early 1980s.
9
  
A component of the growing incidence may have resulted from better diagnostics with the 
faster and more sensitive polymerase chain reaction (PCR) test, genetic drift of the 
bacteria away from vaccine strains, lower vaccination rates and the lack of natural 
boosting of immunity in the presence of waning immunity from both disease and 
vaccination. In response to the increased incidence, booster immunizations were 
recommended for adolescents and adults in 2005.
8,10-12
 This resurgence is most clearly 
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seen among infants, among whom 4,994 confirmed cases were reported in the 2012 
calendar year (126.7 per 100,000 infants).
13
 The year 2012 had many statewide outbreaks 
and may over represent infant cases, however a five-year average from 2008-2012 at 
3,546 cases is still well above the targeted control goals.
14
 Both the annual case counts and 
incidence estimates suggest that the transmission of pertussis is continuing to increase, as 
measured by confirmed disease in the most vulnerable portion of the population. 
1.2. Surveillance  
CDC statistics and recommendations are based on data collected via surveillance. 
Surveillance, the foundation of public health, is “the ongoing collection, analysis, and 
interpretation of outcome specific data for use in planning, implementation, and evaluation 
of public health practice.”
15
 The collection of such data is a proactive process, whereby the 
diseases and conditions are determined to be significant enough to warrant data collection. 
The analysis and interpretation of these data depend on the surveillance system objectives, 
which can be manifold. Since public health intends to protect and improve the health of 
populations, surveillance findings can identify risk factors, outbreaks, and changes in 
reporting or disease presentation.  Ideally, such results will enhance prevention when they 
are shared with the public, and with those who work to improve the public's health, 
ranging from physicians at the micro-level to policy makers at the macro-level. 
Disease surveillance systems are used to ensure a state of awareness and preparedness to 
specific, recognized health threats. These objectives include programmatic evaluation, risk 
group determination, and spatial distribution to better understand the epidemiology of the 
specified diseases.  To be effective, surveillance systems require a formalized health 
system, a disease classification system, and a reliable means of diagnosis. The foundation 
of a surveillance system is derived of two fundamental components; the conditions that are 
reported, and the structural framework of the reporting process.  
Continuing pertussis surveillance is justified because of its preventability, the resurgence 
of cases, the severity of illness in infants, and the extended morbidity in adults. 
1.2.1. Reporting Process 
The Michigan Public Health Code first formalized surveillance reporting in 1883, which 





 Public health legislative powers are retained at the state level, where 
communicable disease incidents are passively reported to state public health departments, 
then voluntarily shared with the federal CDC.
17
 The data are collected to inform “the 
planning and evaluation of disease prevention and control programs, [and] in the 




In the US, diseases are most frequently reported by private physicians and hospitals at the 
local city or county level, before being sent to that state's health department. Notifiable 
conditions are voluntarily reported to the CDC National Notifiable Diseases Surveillance 
System (NNDSS) by the health departments of states and territories.
17
 As reports are 
received, the health departments review cases to examine larger trends and potential 
outbreaks. This should facilitate proper disease identification and follow-up of cases.
14
 
Additionally, automated reporting of laboratory test results is being incorporated at the 
state level to improve specific disease identification.
18-20
 This is being done at the state 
level rather than in local health departments, due to the technical requirements of the 
process as well as the expertise needed to interpret the high volume of reports.  
1.2.2. Notifiable Disease  
Which conditions are determined to be notifiable, is based on various criteria which 
include: incidence, severity, communicability, preventability and public impact.
17
 The 
approval of the Council for State and Territorial Epidemiologists (CSTE), comprised of 
epidemiologists working in state and local levels of government, is required for any 
addition to or alteration of the notifiable diseases list put forth by the CDC. Similar criteria 
are adopted by state health boards to determine the state-specific regulated list of 
reportable conditions; these generally include the federally notifiable diseases.  
The goal of having specified notifiable conditions is to produce rapid disclosure to health 
authorities, which can then be capitalized on to minimize impact of diseases with high 
mortality or severe outcomes by preventing acquisition or speeding up identification of the 
causal agent to mitigate consequences. General classes of notifiable diseases are 
categorized by mode of transmission and include diseases: food or water borne, sexually 
transmitted, zoonotic or vector-borne, respiratory, blood borne and other. While the 
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response to a surveillance event is not part of the surveillance process per se, it should be 
the natural consequence of accurate and timely reporting of notifiable conditions and 
subsequently result in a qualified assessment and communication of the findings. 
To ensure the validity and comparability of notifiable disease reporting, the case definition 
includes a standardized set of epidemiologic, clinical and laboratory criteria for both initial 
reporting and case verification. The case definitions are developed in collaboration 
between the CSTE and the CDC.  Initial reporting guidelines indicate individuals with 
high probability of the disease in question. Disease-specific, case-validation criteria are 
intended to confirm the condition.  
1.2.3. Pertussis, the Illness  
Pertussis is the result of infection with the bacterium Bordetella pertussis. The infection is 
localized to the upper portion of the respiratory system, where these bacteria attach to the 
cilia and excretes a spectrum of toxins. This immobilizes and breaks the cilia, and impedes 
the clearing of the airways resulting in a prolonged cough illness. Infection has three 
stages, catarrhal, paroxysmal and convalescent. Individuals are communicable during the 
catarrhal period until two weeks after the onset of cough.
21
 The incubation period of 
pertussis is a seven to ten days, from exposure to the onset of symptoms.
12
 The catarrhal 
stage has a mild onset and presents as congestion with a low grade fever similar to other 
mild respiratory illnesses.
21
 This stage usually lasts one to two weeks before coughing 
starts.
21,22
 The patients generally cough at night, often in bursts or paroxysms that are so 
severe that the individual cannot breathe until the coughing has passed; often resulting in 
the inspiratory whoop from which the colloquial name whooping cough is derived. These 
bursts of coughing can also result in post-tussive vomiting. The paroxysmal stage lasts 1-6 
weeks.
21-23
 The individual generally feels fine between bouts of coughing.
21,23
 There is a 
wide range in disease severity, vaccinated individuals and those who are older are less 
likely to have cough attributes (paroxysms, whooping or post-tussive vomiting) and tend 
to have fewer paroxysms per day when they do occur. This stage is clinically most severe 
in young infants, as they can turn blue from a lack of oxygen during the paroxysms, and 
have high hospitalization rates.
21
 This type of cough also occurs in a variety of viral 
infections but tends to be mild and of short duration. During the convalescent stage the 
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frequency and severity of the paroxysms decreases. This stage can be as short as two 
weeks but can also last for months.
21,22
 
Diagnosis of pertussis can be made on purely clinical characteristics, according the CSTE, 
if the individual has coughed for more than two weeks accompanied by whooping, severe 
bursts of cough, or vomiting after coughing. Laboratory confirmation of disease can 
identify the bacterium through culture or amplification of the bacterial DNA via PCR.
24,25
  
PCR tests were shown to have an increased sensitivity over culture testing improving the 
diagnostic sensitivity in adolescent and adult rates.
23,24,26-28
 Pertussis can also be diagnosed 
through paired serology which looks for a significant fourfold rise in titer between 
samples taken at an interval of at least two weeks.
28
 This delay in acquiring the second 
sample is problematic for public health purposes, not only because it requires a second 
healthcare visit, but also because an early diagnosis is critical for outbreak management. 
Therefore, research has been done on single serum samples to determine the normal level 
of IgG antibodies against pertussis toxin in healthy adults to be 99% below 20µg/mL.
27
  
These testing protocols were developed using healthy adults with no history of pertussis in 
the previous year, at a time when vaccination with the whole cell pertussis vaccine (DTP) 
was limited to children. The state of Massachusetts has incorporated this serology testing 
as a case confirmatory criterion for those ≥ 11years, but only when the testing is 
conducted at the Hinton State Laboratory Institute.
27,29
  Since the serology testing cannot 
differentiate between antibodies from natural infection and immunization, this single 
serology test is not interpretable for three years after the receipt of a vaccine.
29
 
The peak sensitivity is test specific: culture (week 1) PCR (weeks 1 & 2), serology (weeks 
2+).
28,29
 The sensitivity of both culture and PCR decreases significantly after the second 
week of cough and with age.
28
 Though the PCR is more sensitive than culture, and 
serology more so than PCR in older age groups.
28
  With the inclusion of PCR testing in 
the case definition in 1997, a portion of the increase in reported pertussis incidence may 




Pertussis is treated with macrolide antibiotics commonly, erythromycin, azithromycin and 
clarithromycin.
12,30
 Erythromycin was identified in the 1960s as the most effective 
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antibiotic; it is usually prescribed as 4 divided daily doses over 14 days.
12,31
 This antibiotic 
is known to have low completion rates in part due to the length of the prescription and 
partly because of common gastrointestinal side-effects.
32
 Azithromycin (prescribed 2x on 
day 1 and daily on days 2-5)  and clarithromycin (prescribed twice a day for 7 days)  both 
have shorter course of antibiotics, with fewer pills, are better tolerated and found to be 
equally effective as erythromycin.
30,32
 These characteristics results in better compliance 
among pertussis cases.
33
 Where allergies to macrolide antibiotics exist, trimethoprim-
sulfamethoxazole (TMP--SMZ) is the recommended alternative.
12
 The purpose of 
antibiotic treatment is to both kill the bacteria in infected individuals, and limit the period 
of transmission to others. It is not clear whether the final cough duration is improved. 
Macrolide therapy is also recommended for post-exposure prophylaxis to asymptomatic 
household contacts up to 21 days after cough onset in the primary individual, to decrease 
the probability of infection.  
A recent case report of macrolide-resistant pertussis has been identified; it is possible that 
this bacterial type will become more frequent given the high use of macrolides for 
treatment, and prophylaxis.
34
 This provides additional justification for promoting the use 
of culture testing for suspected cases, as having sample allows for further testing, 
including antibiotic sensitivity and variations in gene expressions.   
1.3. Epidemiology  
1.3.1. Traditional (before 1980 as disease declined) 
Pertussis is diagnosed most frequently in very young children, usually under the age of 
one year, who typically present with more severe disease.  Vaccination of these young 
children against pertussis was added to the recommended childhood vaccine schedule in 
the mid 1940s after a series of field and randomized control trials.
21
 As a result, infection 
in older children and adults, most of whom have a primed immune system either via 
earlier infection or vaccination, have mitigated symptoms and exhibit a shorter duration of 
disease with less severe coughing. 
35,36
 Evidence of this immune response has been 
substantiated with bacterial load counts per nasopharyngeal swab where highest counts 
were found in infants (1.1x106 cells), followed by children (2.1x10
4
 cells), and then adults 
(320 cells).
37
 As pertussis is primarily diagnosed based on clinical presentation, these 
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older cases are less likely to be identified.  Disease in adults was infrequent at the 
beginning of the twentieth century, when cases over 15 years of age accounted for 2.5% of 
the reported cases.
38
 Re-infection has been reported showing that as many as 47% of 
children are infected by pertussis under outbreak conditions within five years of 
completing the initial vaccination series, three doses of the whole cell vaccine, suggesting 
that immunity is not life-long.
35,36,39
  
1.3.2. Resurgence (1980 to present) 
After having experienced the benefits of routine vaccination, pertussis is the only vaccine 
preventable disease (VPD) to have undergone a return to nationwide, endemic 
transmission. The increasing incidence of pertussis could be detected in the 1980s when 
the overall case count was still very low and diagnosis was still based on culture 
techniques (Figure 1.1).
9,40
 This represents a true increase of disease as the incidence of 
pertussis in infants, which experience the most severe disease, has increased from a 1980s 
average incidence of 34.2 to 70.9 per 100,000 infants in 2011, a non-epidemic year.
14,41
 
Infants still face the heaviest disease burden and continue to exhibit the characteristic 
clinical presentation and high hospitalization rates. 
This increase is evident nationally over the timeframe of the study, increasing from a 1990 
average pertussis incidence of 1.7 to 6.1 per 100,000 persons in 2011, a year when few 
outbreaks were reported. 
8,14
 By 2009, adults (≥19 years) comprised 25.2% of the reported 
cases.
8
 The percent of individuals infected in outbreak conditions 5 or more years after 
completing the primary acellular vaccination series (5 doses), is 28.8%.
42
  
1.4. Prevention through immunization 
1.4.1. Challenges of the Whole-cell Vaccine 
Pertussis disease can be prevented or mitigated in individuals who receive routine 
childhood immunization. In the United States, the primary vaccination schedule is most 
frequently given using a combination of antigens against Diphtheria/Tetanus/Pertussis 
(DTP). The original DTP formulation contained inactivated cells of whole pertussis 
bacteria this was used in some form until the late 1990s, there were differences according 
to manufacturer and adjuvants. Because pertussis is toxin mediated and the vaccine 
contained the entire bacterium, the natural immune response results in transitory reactions 
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in as many as half of the children including pain and redness at the injection site.
43
 Disease 
was effectively controlled reaching an all-time low in 1976, after which parental concern 
focused on the safety of the vaccine rather than the risks of infection.
44
  
Side effects of vaccination have included convulsions and hyporesponsive episodes have 
also been reported, without subsequent neurological problems.
43
 Due to the serious nature 
of these events there has been widespread negative publicity resulting from a number of 
reports noting encephalopathy following vaccination. As a point of reference the 
background rate of a first neurological episode within the five days following a notable 
event as been estimated to be 1 in 15,000 among children 3-6 months old.
43
 There are 
three large epidemiologic studies that should be considered.  The largest is the National 
Childhood Encephalopathy Study (NCES) a case-control study in the UK in the early 
1980s, which reported that the pertussis vaccination was associated with a 1 in 140,000 
risk of serious neurological illness in the first seven days after vaccination. These events 
were equally common after the first, second or third doses of vaccine.
43
 The Institutes of 
Medicine (IOM) re-evaluated this study and subsequently concluded, “The evidence is 
consistent with a causal relation between DPT and acute encephalopathy.”
45
 The vaccine 
cannot be linked to serious long term neurologic sequellae, based on findings from NCES 
and both birth cohort studies, the Child Health and Education study and the Collaborative 
Perinatal study.
43
   
The negative press that resulted after the NCES included a television program “Vaccine 
Roulette” and a book “A Shot in the Dark” which fueled concerns that DTP could cause 
brain damage, Reyes’s Syndrome and sudden infant death syndrome (SIDS).
44
  Since 
there was a low prevalence of disease many physicians and parents refused to vaccinate 
with DTP, either by using the alternative DT (Diphtheria/Tetanus) vaccine or refusing the 
vaccine entirely. These perceptions have been mitigated by strong advocacy within 
pediatric and primary-care organizations, and the school based vaccination requirements. 
In other countries this negative press resulted in dramatic reduction of DTP vaccination 
for a period of time, resulting in large pertussis outbreaks within five years.
44
 When 
vaccination coverage was first estimated by the National Immunization Survey in 1994, 
10 
 
the DTP/DT coverage was at 70%. This is naturally an over-estimate of pertussis 
immunity as the DT immunization was included without differentiation at that time.
46
 
1.4.2. Acellular Vaccine Formulation 
Due to these concerns about reactivity of the DTP vaccine, an acellular formulation of the 
pertussis component (aP) was licensed in the USA in 1995, as an equally effective but less 
reactogenic vaccine and the DTP whole-cell formulation was phased out of use by 1999.
47-
49
  The formulation of the vaccine is manufacturer specific, all versions include the 
pertussis toxin (PT), filamentous haemagglutinin (FHA) and some include pertactin (PRN) 
and fimbriae (FIM).
50
   The vaccination series consists of four initial doses given at 2, 4, 6, 
and 12-18 months, with a primary booster at 4 to 6 years. Efficacy of the full DTaP 
immunization series is 88.7 % against reported pertussis.
42
 The unvaccinated have 8.9 
times the odds of acquiring disease when compared to those fully vaccinated.
42
 Since the 
changeover to DTaP, there has been some evidence that the acellular formation may have 
a lower efficacy compared to the whole cell vaccine.
48,49,51,52
 Reduced efficacy estimates 
may partly be a reflection of bacterial adaptation under the immune selective pressure 
against the vaccine strains of the PRN component.
53,54
 
Local reactions to vaccination still occur and include fever, redness, swelling and soreness 
and are estimated to occur in 1 of 4 children.
55
 Some risk can be reduced if the vaccination 
is administered in the thigh rather than the arm in children younger than 36 months of 
age.
56
  Some children with extremely serious reactions to a previous dose of DTaP 
including a life-threatening allergic reaction or suffered brain or nervous system disease 
within 7 days after a dose of DTaP should not receive any additional doses.
55
 Children 
who had a seizure or collapsed, or cried non-stop for 3 hours, or had a fever over 105 
degrees after a dose of DTaP are rare and the physician should be consulted as to whether 




 Recognizing the new adolescent risk group, the Tdap vaccine was formulated adding the 
aP component to the tetanus and diphtheria booster (Td). The two licensed versions of this 
adolescent vaccine both contain PT, FHA and PRN, the one also licensed for use in adults 
also contains FIM elements. The Tdap vaccine has a smaller inoculum of each element 
11 
 
when compared to the DTaP vaccine.
50
 The tetanus and diphtheria components are listed 
in order of the inoculum size. While the pertussis component is listed last since it was 
incorporated into a preexisting vaccine.  Recent changes to the immunization schedule 
include an additional booster shot for adolescents and a one-time booster for adults 
recommended just following the peak of the first nationwide outbreak in the US in 2005. 
These changes have been reactive measures to control glaring increase of disease. . 
1.4.3. Immunization Coverage 
Vaccination prevalence against pertussis has increased from 70% in 1994 to 80.5% in 
2008 for the initial 4-shot series among toddlers, though 95.6% had received the first three 
doses in the series.
46,57
 This improvement in vaccinations in large part due to the outbreaks 
of Measles in the early 1990s which highlighted insufficient vaccination rates. With the 
implementation of the National Immunization Survey in 1994, solid state-based estimates 
of vaccination showed clearly where improvements were needed. The continued emphasis 
on immunization, along with the resurgence of disease has improved vaccination rates 
with 2011 estimates so that 4 dose coverage with DTaP is at 84.6%, and 3-dose coverage 




Within three years since the new recommendation in 2008, Tdap coverage among 
adolescents was estimated at 40.8%.
10
 With the continued press coverage of pertussis, the 
immunization rate has since improved. The most recent estimates (2010) of the Tdap 
adolescent booster, was at 68.7% among those 13-17 years of age in the US.
14
 Since the 
introduction of the adolescent pertussis booster, the pertussis incidence of disease among 
this group has decreased, suggesting that the use of the vaccine was effective among this 
targeted population.
8,14
 While initial uptake was low, numerous states have incorporated 
the adolescent booster as part of their school-based exclusionary immunization schedules 
(32 states for the 2011 school year), which has helped improve coverage.
59
 Vaccination of 
adults (≥ 19yrs) with Tdap is estimated at around 8%. 
11
 
While the coverage of the primary immunization series has improved dramatically, most 
states (except for West Virginia and Mississippi) offer a religious or philosophical waiver 





These refusals can be problematic, because such individuals tend to cluster in space. This 
increases the risk of infection not only to the unvaccinated children themselves, but to the 
entire community as they build a pocket of susceptible individuals in which an outbreak 
can easily occur.
60-62
 In communities with more exemptors 11.0% of the disease is 
attributable to the exemptors, and the more exemptors the higher the reported incidence. 
60-62
   
The increased incidence of pertussis in older age groups allows for a more precise 
estimation of the duration of protection (waning immunity) following the initial 
vaccination series. Historic data suggest that infection-induced immunity is not lifelong, as 
individuals can experience disease again as adults.
35,36
 Therefore, it is unlikely that 
vaccine stimulated protection will be more long-lasting than naturally induced immunity. 
An outbreak-based study in 1962 examined the duration of protection of a three dose 
series of the whole-cell DTP vaccination series and found that five years after the series 
was complete, 47% of individuals were reinfected.
39
 Recent studies regarding the duration 
of protection following a full five-dose schedule of the acellular formulation (DTaP) 
found similar results. 
42,63-66
. 
1.5. Summary and Specific Aims 
1.5.1. Aims 1 & 2: Evaluating the Adequacy of the Surveillance Case Definition 
The resurgence of pertussis into the public conscience after 40 years of relatively few 
cases meant that many younger clinicians were not familiar with the disease, or the 
requirements for surveillance reporting when the collection of the data used in this 
dissertation was initiated. Because of the incorporation of DNA based diagnostic tests into 
the case definition in 1997 and the continuing increase of cases since then, we need to 
have a clear understanding of the nature of the surveillance data being collected, to 
appropriately identify pertussis outbreaks and to create effective immunization strategies. 
Chapter 2 addresses this need by evaluating the surveillance data from the state of 
Michigan for the period 2000-2010, according to the case classification requirements.  
This is the first population-based evaluation of the case classification requirements 
examining the role of PCR confirmation.  
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The primary element of case identification and the surveillance case definition is the 
unique and prolonged cough associated with pertussis. A case confirmation via a bacterial 
culture requires only the presence of a cough. However, a lab confirmation via the newer 
PCR testing accepted by the CDC in 1997 requires a two-week cough minimum duration. 
Because of this discrepancy in the importance of cough duration in case confirmation we 
need to better understand the reporting practices associated with cough duration in order to 
determine the efficacy of the current case definition.  Chapter 3 addresses this need by 
identifying predictors of inadequate reporting of cough duration, in order to provide a 
scientific basis for simplifying and improving the case classification guidelines. 
Streamlining the confirmatory criteria in the surveillance case definitions will improve the 
quality and consistency of the data collected improving comparability of cases across state 
lines. 
1.5.2. Aim 3: Defining Socio-Cultural Risk Factors of Pertussis 
Vaccination is very effective in preventing severe pertussis both for the individual and in 
the local community. However, to be effective the population needs to maintain high 
vaccination levels. The Healthy People 2020 goals are to establish and maintain 95% 
coverage for both the primary vaccination series as well as the adolescent booster.
7
 The 
use of immunizations is based on beliefs and behaviors that are developed based on the 
individual’s environment. Because of the renewed endemicity of pertussis, a more 
complete understanding of the risk factors associated with the socio-structural components 
of the environment is needed so that public health workers can better identify at risk 
populations and develop more effective and targeted prevention programs. Chapter 4 
assesses socio-structural risk factors across US counties for the period 1991-2008. This is 





Figure 1.1 Annual pertussis cases reported to the Centers for Disease Control and 
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Chapter 2  
Validity of Routine Pertussis Surveillance Data in Michigan, 2000-2010 
2.1.  Introduction 
Pertussis is a highly communicable, respiratory infection caused by the Bordetella 
pertussis bacterium.  Illness is characterized by bursts or paroxysms of coughing 
frequently followed by an inspiratory whoop which is the source of the common name, 
whooping cough. The clinical course of disease begins with a non-specific catarrhal stage, 
of general cold symptoms and a low-grade fever. After approximately one week, severe 
coughing spells begin where the patient cannot breathe between coughs; this is the 
paroxysmal stage it can last up to two months. The final stage of illness is the 
convalescent stage during which the severity and frequency of the coughing declines over 
time.
1,2
  The most severe morbidity and mortality occur in children under 5 years, 
especially in those less than 1 year of age, and those who are not fully protected through 
immunization.
3
 Additionally increasing morbidity is being seen among children in early 
adolescence, even in those fully immunized.
4
 
The Council for State and Territorial Epidemiologists (CSTE) has established a case 
definition for each of the nationally notifiable diseases identified by the Centers for 
Disease Control and Prevention (CDC) (http://wwwn.cdc.gov/nndss/) this list has included 
pertussis since 1922.
5,6
 The purpose of a case definition is to define illness using explicit, 
tangible criteria based on clinical, laboratory and epidemiologic information to maintain 
both validity and reliability in surveillance data collection, ensuring comparability across 
reporting source and time. Surveillance data are used to understand the magnitude and 
distribution of pertussis cases and changes in the epidemiology of the condition. 
Evaluation of the case definition criteria has become important with the U.S. national 
upsurge in cases, the recognition of a new risk group in adolescents, and the increased use 
of DNA tests for diagnosis. The 2010 outbreak in California reported significant disease 
among vaccinated individuals as soon as 5 years after the completion of the primary 
21 
 
immunization schedule, this has fueled concern regarding the long-term efficacy of the 
acellular vaccine formulation.
4,7,8
 These concerns have justified the 2005 recommendation 
of a Tdap booster at 11-12 years and once among adults. Surveillance data is also used to 
evaluate the efficacy of programmatic changes in prevention and control efforts.
3
 
Therefore, it is imperative that the case definition be utilized consistently and as intended, 
to appropriately inform other public health decisions. Our analysis seeks to understand the 
utilization of each component of the case definition criteria, to determine the reliability of 
the data with regard to the intended standard.  
The current CDC criteria (1997) for pertussis case status classification, the standard for 
ascertaining a case as confirmed or probable, are complex (Table 2.1). The distinction 
between the two is that a confirmed case has some laboratory indication of B. pertussis, 
either from the patient himself, or through epidemiologic linkage that is a close contact 
that tested positive, while a probable case is confirmed by the clinical presentation alone. 
These CDC case definitions have centered on cough as the central component of case 
identification, with a special focus on its duration. The cough criterion is necessary when 
laboratory testing is unavailable or when laboratory tests have low sensitivity among 
clinical cases, i.e. 7% sensitivity for culture.
9,10
 The CDC case definition recognizes a 
positive bacterial culture as the gold standard, when an isolate is obtained diagnosis is 
definitive; any additional cough description cannot improve the certainty of diagnosis. 
However, other DNA tests like the polymerase chain reaction (PCR), included in 1997, 
while greatly increasing the sensitivity of laboratory diagnosis,
10-12
 have the possibility for 
false positive results without the ability to verify the conclusion. In such cases cough 
attributes and duration increase the confidence in the diagnosis. Shakib et al. examined 
PCR-positive pertussis cases in light of the cough criteria and determined that a case 
definition with a cough of at least 7 days, rather than of 14 days, would allow an increase 
in confirmed case status from 88% to 95%.
13
 The present study is designed to expand on 
that analysis by examining all pertussis cases reported in Michigan between 1 January 
2000 and 31 December 2010, many of whom do not include a positive PCR test, with 
respect to the reported elements of the case definition, including cough duration. 
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The U.S. surveillance system functions primarily through a passive reporting mechanism, 
which minimizes resource expenditures until potential cases are identified. To function 
effectively, passive reporting systems must ensure an awareness of the conditions, and the 
willingness and capacity to report of the primary healthcare providers. This system is 
plagued by under-reporting and incomplete data collection.
14,15
  During 1985-1988, the 
overall surveillance system sensitivity for routine passive data collection of pertussis, by 
the CDC, was calculated at 35% when compared with hospital discharge data.
16
 Since 
then, the development of electronic reporting and automated laboratory reporting has 
increased the overall completeness, sensitivity, and timeliness of the reporting system.
14
 
Evaluation of a surveillance system examines the data collected to either an external 
standard, or to another data collection system to evaluate data quality, timeliness of 
reporting, and efficiency of the reporting process. Such evaluations determine whether the 
surveillance system is functioning effectively in swiftly and appropriately identifying 
cases of pertussis. Additionally discrepancies can provide insight into informational 
misinterpretations, procedural gaps, and provide context to characterize the reported cases 
in reference to both the general population and unreported cases. There have been changes 
in the reporting of pertussis over the past decade, including the introduction of web-based 
reporting and automated lab result reporting against a background of a significant 
resurgence of cases. The objective of the present research was to qualitatively assess the 
validity of pertussis cases as reported through routine passive public health surveillance in 
the state of Michigan, and thereby address the utility of the reporting system as well as the 
effectiveness of the case definition criteria. 
2.2. Materials and Methods  
The database for this analysis included all cases of pertussis reported to the Michigan 
Department of Community Health (MDCH), between 1 January 2000 and 31 December 
2010, as part of the state's routine surveillance of communicable diseases. The original 
data set contained 5,738 completed pertussis case investigations, of which 938 were filed 
as ‘Not a Case.’ The remaining 4,800 records were submitted with either a probable or 
confirmed pertussis case status and were, therefore, reportable. Six of these records had a 
laboratory result indicating Bordetella parapertussis infection, and were hence excluded 
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from all analysis. The data acquisition and analysis plan was approved by the Institutional 
Review Boards of the University of Michigan and MDCH.  
2.2.1. Reporting Systems 
During the study period, two electronic systems were used to transmit information 
regarding reportable diseases in Michigan from local health departments (LHDs), primary 
care providers and hospitals to the MDCH. The reportable diseases are specified in the 
Michigan Compiled Laws, specifically the Communicable Disease Rules, and include 
pertussis.
17
The first electronic system was a DOS-based, reporting system (1992-2004) 
which transmitted records on a weekly basis only from LHDs to the MDCH.
17
In June 
2004, the Michigan Disease Surveillance System (MDSS) was implemented as a web-
based disease reporting tool allowing for real-time access to communicable disease data 
by public health partners. The MDSS diversified the reporting sources to include not only 
LHDs, primary care providers and hospitals, but also includes automated reporting of 
laboratory results. With the numerous origins of case reports the system includes de-
duplication functions, whereby the health department can choose to merge two reports into 
a single continuous record. MDSS also includes numerous other analytic and alert 
functions to facilitate public health response.  
Providers entering data into the system are asked to complete the MDCH case report form, 
which includes demographic factors, contact information, and clinical information 
regarding the disease event. (See Appendix A for the MDCH pertussis case report form.) 
Healthcare providers and LHDs have the ability to review and edit data on their cases, 
immediately improving the overall completeness of demographic variables by roughly 
20%.
17
 Web-based reporting occurred on average five days earlier in the clinical course of 
illness, which is an expected improvement based on automatic updates rather than the 
weekly batch transmissions of the earlier system.
15,17
 These values are comparable to other 
studies evaluating the implementation of electronic reporting systems,
14




2.2.2. Data Modifications 
While overall reporting has improved data completeness, many of the case report variables 
are still characterized by incomplete reporting. In order to improve the completeness of 
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key indicators, these variables were re-coded based on other information in the case report 
to minimize non-response, and increase the potential analytic sample size. For example, a 
case was coded as cough = ‘Yes’ when the record reported any of the following: a cough, 
a cough attribute, final cough duration, or an affirmative for still coughing at the final 
interview. For all variables a response of ‘Yes’ indicates a true response, a coded ‘No’ was 
interpreted as the absence of a yes, including both a negative and non-response. 
Most pertussis cases received an antibiotic; the antibiotic date was one of the most 
completely recorded secondary dates (87.8% reported). Time to the first prescription of 
antibiotics was calculated in days from the cough onset date to the date of first antibiotic, 
and was used as a proxy for initial doctor visit. The time interval information was also 
calculated between cough onset and PCR test date, the most frequently reported lab test, 
as well as from cough onset to diagnosis date, to determine the timeline of medical care in 
regard to clinical and diagnostic assessment. 
The date of disease was created to have a single variable indicating when in time the case 
occurred. In this analysis, occurrence was defined by year. Disease date was drawn from 
the reported date of cough onset whenever possible. This variable was utilized both for its 
completeness (91.3 %) and the fact that it is the single most memorable event for the 
patient to recall in the clinical disease timeline. The variable “onset date” was not selected 
because a large portion of the records report the same date for both general onset and 
cough onset. This is exceedingly improbable, since the initial catarrhal stage generally 
lasts seven days, generally with mild symptoms and insidious onset. Therefore, when both 
dates were equivalent it is more likely that the date reported was indeed cough onset due 
to its more dramatic presentation, which left only 6.9% of records with a valid onset date. 
If cough onset date was not available, or if it could not be calculated based on the final 
interview date, i.e. the final point of contact with the case, and the final cough duration 
date, other dates in the record were used to approximate the disease date. Estimated dates 
were selected based on dates of the following, in order of priority: illness onset, first 





2.2.3. Data Analysis  
This analysis was an evaluation of pertussis cases reported to the MDCH with a probable 
or confirmed cases status cases. These designations are given according to the reporting 
criteria established by CSTE and the case status definition criteria.
6
 Reported clinical data 
were compared across the cases status classifications for comparability using frequencies 
and medians, as the continuous variables were not normally distributed. T-tests were used 
for comparisons of normally distributed data, and the Wilcoxon Two-Sample test was 
used for comparisons of medians when testing for significant differences between 
descriptive categories. 
Records were also examined for the completeness of the auxiliary information recorded 
(e.g. dates, treatment, testing, demographics), with specific interest in changes over the 
study period. All records with at least a reported cough were examined (N=4,586: 95.7%). 
The variables examined included dates (cough onset, diagnosis, antibiotic, PCR), 
demographics characteristics (e.g. birth date, race, sex, Hispanic ethnicity) and clinical 
information (cough duration, whooping, paroxsysms, post-tussive vomiting, apnea, 
antibiotic prescribed). The temporal distribution of completeness was examined to 
evaluate changes in the reporting environment that occurred between 2000 and 2010 using 
simple linear regression.  
The subset of investigations that were labeled ‘Not a Case’ was analyzed to determine the 
proportion of false negatives within each case status classification. The data were sorted 
first for any positive laboratory test (i.e. culture or PCR) and for epidemiologic linkage. 
Then each positive record was reviewed for the presence of a cough attribute and cough 
length. These records were also examined with respect to the year of occurrence to 
determine the distribution over the study period.  The false negative rate was calculated to 
evaluate under-reporting. 
2.3.  Results 
Of the 4,794 pertussis records reported to MDCH with a confirmed or probable status 
between 1 January 2000 and 31 December 2010, the breakdown according to the 
surveillance reporting pertussis criteria put forth by the CSTE for surveillance is shown in 
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Table 2.2. These criteria are the initial indicator which would lead the primary care 
provider to suspect pertussis and report the potential case. By definition, the entire dataset 
met reporting criterion 5, namely that a healthcare provider made a diagnosis of pertussis. 
Forty-five percent (N=2,157) of records met two reporting criteria, and 1,462 records 
(30.5%) met more than two reporting criteria. The breakdown of the full case status 
criteria in Table 2.1 is illustrated in Figure 2.1, where the CSTE confirmed case status 
criteria were met in 2,050 (42.8%) of records, and 1131 (23.6%) met the probable status 
criteria.  
There was a significant difference in cough duration between those who reported at least 
one of the three required cough attributes (i.e. whooping, paroxysms or post-tussive 
vomiting), and those who did not (Table 2.3). Paroxysms were reported twice as 
frequently as either of the other two criteria. People reporting a specific cough attribute 
coughed at least 2.7 days longer on average than those who did not specify a cough 
attribute. This was most clearly evident with people who reported paroxysms and those 
who did not report paroxysms, where the mean cough duration differed by more than one 
week.  
Comparison of the clinical characteristics by ascribed case status is shown in Table 2.4.  
Both confirmed and probable cases had a similar distribution of the median time from 
cough onset to seeking medical attention (Antibiotic Date). Of the cough attributes 
whooping was more frequent among the confirmed cases (6%, T-test p< 0.01) and 
paroxysms were less frequent (- 4% T-test< 0.01) when compared to the probable cases. 
PCR tests were frequently conducted on the day that antibiotics were first prescribed, 
except in those confirmed by epidemiological linkage where antibiotics were prescribed 
an average of 5 days prior to testing.  The PCR test sample was collected roughly two 
days later than antibiotics were prescribed, an average of two weeks after the onset of 
cough, and often upwards of three weeks. (Data not shown.)  This time to testing 
significantly decreases the probability of a positive result.
10,18
 Those with a positive lab 
test compared to those without tended to be younger (p<0.01), less likely to be part of an 
outbreak (p<0.01), more likely to have post-tussive vomiting (p<0.01), and more likely to 
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have received antibiotics a earlier (p<0.01). Increasing age and longer time to diagnosis 
was seen with decreasing certainty of case status (moving from left to right in Table 2.4).  
The cases labeled as “Suspect” in Table 2.4 include cases that failed to meet the confirmed 
or probable case status classification based on insufficient cough duration, but exhibited 
both a cough attribute and a positive laboratory indicator. The “Other” column describes 
cases which did not meet the proposed criteria. Those who failed the case status 
classification due to insufficient cough length, were of similar age and attribute 
distribution to their counterparts in the confirmed classification. They are distinct because 
they sought medical care in the first week of cough and were generally diagnosed prior to 
fourteen days.  
Cases marked as part of an outbreak were most frequent among those confirmed by 
epidemiologic linkage. One quarter of those with a probable status were reported as 
occurring during an outbreak. There is no quantitative definition of a pertussis outbreak, 
but it would require a number of cases in the same place and time, linked in some manner. 
The frequency of outbreak associated cases among the epidemiologically linked and 
probable cases may be due to case ascertainment or follow-up differences that occur in 
high intensity outbreak situations, such as active case finding or more complete case 
follow-up. There was no significant difference in the use of PCR testing between outbreak 
cases (49.0%, 95%CI (47.6 – 52.7)) and endemic cases (46.1%, 95% CI(48.8 – 51.0)). 
The completeness of variables that comprise the case report is selectively presented in 
Figure 2.2 to show the annual variability over the study period. Most variables remained at 
relatively constant levels of reporting. The reporting of critical disease variables like 
Cough Onset Date and the presence of a Whoop when coughing(data not shown), 
maintained a high reporting rate of 96.6% and 90.5% respectively. Other descriptive 
variables like Hispanic Ethnicity (62.9%) and Race (37.1%) held steady at lower levels. A 
slight decline was observed for Final Cough Duration and Cough Onset Date, most likely 
a by-product of the increasing volume of cases. Increasing completeness was seen in both 
Diagnosis and PCR dates. The Diagnosis Date change coincides with the introduction of 
the MDSS in 2004. The PCR increase is more gradual, roughly 5.7% per year and is not 
clearly linked to the introduction of the MDSS. Rather, it probably represents the 
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increased familiarity with and use of PCR testing as part of the diagnostic process. A 
consistently high level of reporting was evident for other clinical and demographic 
variables (Data not shown, see appendix B.) including: birth date, sex, whether antibiotics 
were prescribed, date of antibiotics, apnea, paroxysms, post-tussive vomiting. 
The evaluation of records classified as “Not a Case,” resulted in the identification of five 
additional confirmed cases, and thirteen suspect cases. The distribution over time is 
illustrated in Figure 2.3, and clearly occurs in parallel to outbreaks. Eight of these cases 
were still coughing at the final interview, including all confirmed cases. Of the three 
suspect cases one coughed 9 days the other 11 days while the third did not report a cough 
length. Seven of the ten remaining records failed to report cough length and the remaining 
three were no longer coughing.  The overall false negative reporting rate was 4.2/1000 
case reports since 2005.  
2.4. Discussion 
These results show that there was a high consistency in the data, over the study period, 
even with the changeover to internet-based reporting. The reported pertussis cases were 
correctly identified by the case definition and case classification criteria of CDC. Of the 
reported cases in this dataset 84.2% have a high clinical probably of being true pertussis 
cases; 66.4% met the reportable case definition, another 15.5 % had a positive PCR test 
and 2.3% were epidemiologically linked with a reported cough attribute. Of those reports 
that failed to verify the pertussis diagnosis, it is mostly based on incomplete cough 
duration. This brings into question two important factors in the utilization of the current 
case definition. Firstly, whether the of cough length criteria is necessary, in the presence 
of a positive laboratory indication (culture, PCR or epidemiologic linkage), and if so what 
duration would be required. Secondly, a PCR positive result is frequently being reported 
as a confirmed case, but only 70% of the cases meet the 14 day cough requirement. This is 
a misinterpretation of the classification criteria, where the process of confirming a case by 
culture and PCR testing differs. A case definition must be as straight forward as possible; 
the different requirements simply among the confirmed criteria make this a challenging 
case definition.  
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The current CDC clinical case definition for a probable case has been shown to have 96% 
sensitivity and 35% specificity among culture positive or direct fluorescent antibody 
(DFA) positive cases.
18
DFA is no longer considered a valid confirmatory test, and has 
been replace by PCR. As many as 81% of urgent care providers in another study were not 
aware that clinical pertussis is itself reportable, often waiting first for a positive laboratory 
result.
19
 The inclusion of PCR as a confirmatory test has significantly increased the 
sensitivity of laboratory testing and the number of confirmed-status cases, as the PCR test 
detects the bacterium three times more frequently than culture.
10,20,21
 This brings into 
question the importance of the cough criteria among PCR positive cases. As Shakib et al 
reported most PCR positive cases cough for more than seven days if they also present with 
a cough attribute, which agrees with our results.
13
  
Due to the similarity between suspect cases and their confirmed counterparts, perhaps 
suspected cases with a cough attribute (whoop, paroxsysms, and/or post-tussive vomiting) 
who also have a positive lab indication (PCR or epidemiologic linkage) should be 
considered a confirmed case. It would seem that cough duration does not add much to 
these criteria, as the presence of a cough attribute already strongly indicates pertussis. 
Additionally, the pertussis case classification system is relatively complicated, and the 
presence of two cough durations would likely add to the confusion, especially since it is 
not critical for cases with a positive laboratory indicator. Based on our results, the current 
recommendations for confirmation via culture seem reasonable, as roughly 10% of these 
cases did not present with a cough attribute. The clinical case definition, used for probable 
cases, should also be maintained as currently recommended, 14-plus days of cough with a 
cough attribute, for those who either test negative by PCR/culture, or are unable to be 
tested in a timely or adequate manner. 
Under these proposed guidelines 11.6% of those reported who currently fail the case 
definition due to insufficient cough length would also be confirmed cases. The 14.1% of 
cases listed as ‘Other’ in our analysis should not be reported due to lack of adequate 
clinical verification in the case report. After reviewing all events which had inaccurate 
case status labels base on information in the record, there was a slight over-reporting of 
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“true” cases at about 11/1000 reports. This may partially be due to incomplete reporting of 
classification criteria, most commonly the duration of cough.  
The consistency of the completeness of most variables suggests the reliability of the 
reporting system even with the change to internet-based reporting. The implementation of 
an online reporting system probably mitigated the reporting burden of the four-fold 
increase of annual pertussis cases seen during the 2000s, resulting in only minor declines 
in completeness in a few variables such as cough onset date and cough duration. Disease-
specific variable completeness did not fall below 90%, maintaining a high level of 
reliability. There were also some improvements in data completeness, for example,  with 
the diagnostic date that stabilized in the high 70 % range, suggesting an increase in 
reporting capacity and “buy in” by healthcare providers. This represents an improvement 
in surveillance management, as a side benefit of the MDSS system, providing healthcare 
professionals the opportunity to review their cases. Pertussis is now recognized as an 
important contemporary issue, affecting an expanding age range of people. Nevertheless, 
one study in 2007 reported that nearly half of all family practitioners had never diagnosed 
a case of adolescent pertussis.
22
 
Data consistency and accuracy are major challenges of a passive surveillance system, and 
reflects fluctuating resource availability including funding, personnel and interest. Our 
study covers a decade of increasing interest in both pertussis and reporting mechanisms, 
and while resources are known to fluctuate across time and within a given health 
department (e.g., when local outbreaks are recognized), there is a consistently high level 
of reporting the clinically important data. There is also occasional external resource 
supplementation in the form of personnel or finances from the state health departments or 
from the CDC, such as occurred during the study with the influx of post 9-11 bioterrorism 
funding to assist in the electronification of reporting systems, which in part helped 
facilitate the introduction of the internet-based MDSS system.
17
   
The reported data were reliable with consistent and high completeness of the most 
important clinical variable, even with the increased work load and detailed case form. The 
internal validity of the reports is also adequate when compared to the CDC standard case 
definition, but is plagued by incomplete reporting such as submitting a cough length of 
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less than fourteen days but noting that the patient is still coughing. After an in-depth 
deconstruction of reported cases in light of the current pertussis case definition criteria, we 
recommend an update of the pertussis case definition, pertaining to cases with positive 
PCR tests or epidemiologic linkage and recommend that the cough attribute criteria be 




Table 2.1 Criteria used to verify pertussis cases analyzed in this study 
Probable Case (a clinical case):
*
 
–  Cough ≥ 2 weeks  
WITH 




 is a probable case with laboratory confirmation via: 
–  PCR positive 
OR 
–  Epidemiological linkage to a laboratory-confirmed case 
 







–  Cough  
WITH 
–  One of the following: paroxysms, whoop, or post-tussive vomiting  
AND  
–  Bacterial confirmation via:  
–  PCR positive  
     OR 
–  Epidemiological linkage to a laboratory-confirmed case 
*




  This is a NOT a CDC established case status definition; it was created for the purposes 





Table 2.2 Criteria for reporting a suspected case of pertussis to public health 
authorities, and the total number and percent of 4,794 cases meeting that criterion.
23
  
Reporting Criteria N % 
1. An acute cough illness of any duration with an inspiratory whoop 1625 33.9 
2a. Any person with isolation of Bordetella pertussis from a clinical 
specimen 
472 9.8 
2b. Any person with a positive PCR test for B. pertussis 2037 42.5 
3. Any cough illness greater than 2 weeks duration in a person who 
is a contact of a laboratory-confirmed pertusiss cases. 
624 13.0 
4. Any cough illness greater than 2 weeks duration in a person who 
is a member of a defined risk group during an outbreak 
570 11.9 
5. A person whose healthcare record contains a diagnosis of 
Pertussis 
4794 100.0 
6. A person whose death certificate lists Pertussis as a cause of death 





Table 2.3 Average cough duration by cough attribute among all reported pertussis 
cases in Michigan, 2000 - 2010. 





Any Attribute  1+ 3,269 33.7  
   No Attributes 342 24.4  
Whoop 1,326 34.4  
   No Whoop 2,009 31.7  
Paroxysms 3,069 33.9  
   No Paroxysms 429 25.7  
Post-tussive vomiting 1,827 33.9  
   No vomiting 1695 31.1  
* There was a significant difference in mean cough duration, based on a pooled T-test, 
between those who reported the attribute and those who did not, in all categories at a p-value 




    
Table 2.4 Descriptive characteristics cases of pertussis in Michigan, 2000 – 2010, according to case status. 
  Confirmed Probable Suspect  Other 















Median Age (Yrs)  















Median Cough Length 
(Days) (IQR) 
24 (17-37) 26 (19-36) 33 (23-50) 33(22-50) 11(8-12) 10 (6-12) 17 (10-29) 
Still Coughing (%) 85.3 87.9 68.1 81.4 80.6 70.8 66.4 
Outbreak (%) 8.8 14.2 32.6 24.6 4.4 15.3 11.7 
Cough Attribute Present (%) 90.8 100.0 100.0 100.0 100.0 100.0 41.2 
Whoop 59.1 41.6 46.2 40.6 39.8 45.2 15.8 
Paroxysms 87.1 95.2 97.7 97.6 94.4 96.4 42.6 
Post-tussive Vomiting  62.6 59.2 45.4 56.9 54.3 45.5 25.2 
Median Time from Cough 
Onset to: 
       
Antibiotics (IQR) 11 (6-18) 12 (7-18) 15 (7-23) 14 (7-24) 7(4-12) 9(3.5-13) 8.5 (3-17) 
Diagnosis (IQR) 16 (10-25) 15 (10-23) 19 (11-29) 21 (13-37) 10(6-15) 13 (8-22) 15(7-30) 
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Chapter 3  
Routine Surveillance of Pertussis in Michigan, 2000 – 2010: 
Analysis of the Cough Criteria of the Clinical Case Definition.
3.1.  Introduction  
Pertussis, a common pediatric respiratory illness caused by the bacterium Bordetella 
pertussis, is clinically diagnosed based on cough characteristics. The most important of 
those characteristics is cough duration, which has been the primary component of the 
formal case definition used for the purposes of public health surveillance. More 
descriptive factors known as cough attributes are also key to the case definition and 
include the paroxysmal nature of the cough, inspiratory whooping, and post-tussive 
vomiting.  Previously, the pertussis case definition used by the World Health 
Organization (WHO) (1991) required 21 or more days of spasmodic cough.
1
 In 1990, the 
U.S. Centers for Disease Control and Prevention (CDC) instituted a pertussis case 
definition which requires a minimum of 14 days of cough, with the presence of at least 
one cough attribute.
2
 Clinical diagnosis can be confirmed using laboratory testing for the 
presence of B. pertussis based on either culture or polymerase chain reaction (PCR) 
testing, although it is progressively more difficult to detect the bacterium after the second 
week of cough. Currently, cough duration is not required for disease confirmation if a 
positive laboratory culture of B. pertussis has been obtained.  
The cough’s attributes and its protracted duration are definitive of a B. pertussis 
infection; 95% of pertussis cases can be correctly diagnosed if coughing lasted for at least 
21 days and was accompanied by choking fits.  In the presence of a cough attribute, the 
diagnosis could be made earlier.
3
 A clinical diagnosis of pertussis is highly preferred 
because culture sensitivity is very low as evidenced in one study where only 7% of 
specimens were culture positive in a sample of serology-positive, suspected cases.
4
 
Cough duration is also important to prove the accuracy of diagnosis when introducing a 
new laboratory test, such as the more sensitive PCR tests, which had 21% sensitivity 
among the previously mentioned suspected cases tested by culture.
4




formally accepted as a confirmatory test for pertussis by the CDC in 1997 but only in 
cases where a clinical diagnosis had been made.
2
 As noted in chapter 2, Michigan 
physicians have been using PCR test with increasing frequency over the last decade to 
diagnose and confirm cases. In the context of this increased use of PCR, Shakib et al re-
evaluated the cough duration criteria among PCR-positive cases that also had a cough 
attribute.
5
 They found that 88% of PCR-positives met the 14-day cough duration as 
specified in the CDC case definition, but if the required cough length was shortened to 7 
days, then 95% of the cases would have been confirmed. 
As a notifiable infectious disease, all cases of pertussis are required to be reported to local 
public health authorities. All surveillance data are the result of an unintentional case 
exclusion bias, which means that people who tend to delay medical care will be under-
represented in surveillance data. When more active case finding occurs, due to 
recognized outbreaks, this bias may be reduced because those who would otherwise delay 
care are brought to the attention of healthcare providers earlier in the course of illness. 
This bias will make delayed cases appear to be more severe. Initially this is due to cough 
length, but secondarily because the less serious cases will never seek care and therefore 
not be included in the surveillance data. Cases may also be excluded for other unrelated 
reasons due to misdiagnosis or lack of reporting, as in all public health surveillance data. 
3.1.1. Role of Antibiotic Treatment 
Some antibiotics such as erythromycin, a macrolide, have shown bactericidal capacity 
that results in negative specimen samples in as few as two days in both hospitalized 
patients and laboratory cultures.
6
 However, the frequently prescribed ampicillin, a beta-
lactamase, is not effective in treating B. pertussis infection and can extend the period of 
positivity to an average of 20 days after the start of treatment; this is a week longer than 
would be seen in untreated patients.
6
 The cough symptoms are not as sensitive to 
antibiotic treatment, though ampicillin results in about 10 extra days of cough.
6
 Similar 
results showing the effectiveness of erythromycin, but not ampicillin, have been reported 
in other studies.
7,8
 While the CDC pertussis treatment bulletin reports that use of 
antibiotics result in a shorter course of disease,
9




of cases until coughing ends show no effect of antibiotic therapy on cough length, even 
when erythromycin is prescribed as prophylaxis.
6,10,11
   
Studies based on surveillance data rarely consider the case exclusion bias, and by 
ignoring this will suggest that earlier treatment shortens cough duration. 
1,12,13
 However, 
the timing of treatment in such datasets creates an artificial association between treatment 
and cough duration, as those who seek care earlier would have a shorter average cough 
duration when compared to others who came in later, especially when there is incomplete 
reporting of cough length. Since there is insufficient compelling data to suggest that 
cough duration is shortened with antibiotic treatment, the primary purpose of treatment is 




3.1.2.  Objectives 
The pertussis case definition components (Table 3.1) shown in their entirety, involve five 
different ways to identify pertussis cases for surveillance purposes.  Four of these require 
a 14-day cough in addition to other criteria. The fifth, those cases defined by a positive 
culture test (#4) are not required to meet a specific cough length. As indicated in chapter 
2, those who were reported with an insufficient cough (less than 14 days) according to the 
pertussis cases confirmation criteria sought medical attention earlier and were also 
diagnosed prior to 14 days. Thus, analyses in chapter 3 aim to evaluate the predictors of 
sufficient clinical cough criteria among surveillance cases reported as either probable or 
confirmed. In particular, this analysis determines whether there are systematic differences 
between those who reportedly met the 14-day criterion and those who did not, and 
determine whether and how this should affect the case definition.  
3.2. Materials and Methods 
The database for this analysis included cases of pertussis reported to the Michigan 
Department of Community Health (MDCH), during the 11 years from 1 January 2000 
through 31 December 2010, as part of the state's routine surveillance of communicable 
diseases. The original data set contained 4,800 records submitted as either a probable or 
confirmed pertussis case. Six of these records had laboratory results indicating Bordetella 




were excluded when no evidence of cough was contained in the record, this totaled 184 
reports. An additional 1,177 records lacked valid information for at least one of the 
following variables: age, cough duration, or antibiotic, leaving a total of 3,433 records 
(71.5% of the original database) for analysis. Records which are complete for this 
additional information are more likely to have had a closer relationship with either the 
primary care provider or a health department worker for disease follow-up.  The data 
acquisition and analysis plan was approved by the Institutional Review Boards of the 
University of Michigan and the Michigan Department of Community Health.   
3.2.1. Reporting Systems 
During the study period, two electronic systems were used to transmit information on 
reportable diseases from local health departments (LHDs), primary care providers 
(PCPs), and hospitals to the MDCH. These reportable diseases are specified in the 
Michigan Compiled Laws, Communicable Disease Rules, and include pertussis.
15
 A 
DOS-based reporting system that functioned during 1992-2004 transmitted records on a 
weekly basis from only LHDs to the MDCH.
15
 In June 2004, the Michigan Disease 
Surveillance System (MDSS) was implemented as a web-based disease reporting tool, 
allowing for real-time access to communicable disease data by public health partners. 
The MDSS included information from not only LHDs, PCPs, and hospitals; but has 
emphasized the inclusion of electronic laboratory reporting as well.  
Any provider entering data into either electronic system was asked to complete a 
standardized MDCH pertussis case report form, which included demographic factors, 
contact information, and clinical information regarding the disease event. (See Appendix 
A for the MDCH pertussis case form.) Healthcare providers and LHDs can review and 
update their case reports, improving the overall completeness of demographic variables 
by about 20%.
15
 The MDSS system also shortened the reporting interval to MDCH by 
roughly five days, depending on the disease.
15,16
 These values are comparable to those 
reported in other studies evaluating the implementation of electronic reporting systems,
17
 







3.2.2. Variable Re-coding 
As these data are passively reported to the MDCH, most variables have some missing 
values. Thus, variables were re-coded to minimize the effects of missing data, as 
described below, thereby increasing the potential sample size that was analyzed. The 
MDCH pertussis investigation form (Appendix) codes the prescribed antibiotics with the 
numbers in first column in Table 3.2; the ‘Original’ column shows the data as submitted. 
Records with an unknown or missing code but with information on antibiotics in free-
form text were coded manually for both the first (579 records) and second antibiotic (27 
records), shown in the final three columns. Information on the second antibiotic was only 
used when there was missing or unspecified information in the previous two columns.  
The coding prioritized use of an MDCH code when included in the free-form text, where 
it was considered the primary antibiotic. For multiple entries, the initial antibiotic was 
selected. In the absence of an MDCH antibiotic code the following were selected in order 
of preference: a macrolide, a specified antibiotic, otherwise the first listed. Trade names 
(e.g. Bactrim, Ketek, Keflex, Omnicef, Rocephin, and Z-pak) were assigned to their 
appropriate classification. Group 11 was redefined as second generation cephalosporins, 
and group 12 as third generation cephalosporins. The coding scheme was collapsed into 
three broader antibiotic classes, due to the small sample size in specific sub-categories.
18
 
Two aspects of cough length were examined; the first was reported cough length at the 
final visit, and the second a constructed minimum duration cough length. Duration of 
cough was reported in 75.2% of all records. Of those who reported a final cough length, 
81.4% were still coughing at the time the report was made. The minimum cough duration 
was created by using either the reported cough duration, or the time from cough onset to 
antibiotics, whichever was longer. The rational for this was that the individual would not 
have returned to the doctor’s office if their coughing had resolved. 
The first reported date of antibiotic prescription was used as a proxy for healthcare 
seeking behavior, or the initial healthcare visit. The data were separated into four groups 
that related the date of antibiotics to the cough duration: pre-cough, 0 – 6 days, 7–13 days 




attention, and stopped coughing, would not be included in the dataset, thus inducing 
selection bias.  To the extent that this occurred, the dataset does not fully represent the 
entire ill population. 
The date of disease onset was drawn from the reported date of first cough, whenever 
available. This variable was used due to the extent of completeness (91.3 %) and because 
it is the most distinctive event in the course of disease, therefore likely to be accurate. If 
the cough onset date was not available, or if it could not be calculated based on the final 
interview date and the final cough duration, other dates in the record were used to 
approximate the disease onset. Estimated onset was selected based on dates of the 
following, in order of priority: disease onset, first use of antibiotic, PCR or other testing, 
final interview. The disease onset date was simplified to year of event for this analysis. 
The data include a number of dichotomous variables. A summary of the data as received 
is reported in Table 3.3. Due to the high proportion of unknown or missing responses, 
and to retain records for other analysis, these dichotomous variables were re-coded so 
that a ‘Yes’ is retained, but that ‘No’ could refer to either a reported absence of the 
clinical characteristic, or an absence of report. Additionally the variable regarding 
vaccination should be interpreted as evidence of a DTP/DT vaccination record, and the 
unknown and missing records were included with the ‘No’ category meaning that no 
record of vaccination was available. This interpretation was based on the free-form 
responses provided with the conjunct variable asking about the “reason not vaccinated 
with three or more doses”. 
3.2.3. Quantifying the effects of the case exclusion bias  
Since the Suspect Cases identified in Chapter 2 who failed only cough length also 
appeared to seek medical attention earlier in the course of disease, it was thought that 
earlier treatment may have resulted in shorter cough duration. To determine whether 
early and late healthcare seekers produce different cough duration data regardless of 
antibiotic use, out data was simulated in SAS using a log-normal distribution of reported 
cough duration, based on the cough durations reported in the MDCH data.) The dataset 
was left truncated by week to mimic the effects of delayed care seeking and the resulting 




of seeking medical attention, were considered: <7 days, 7-13 days, 14-20 days, 21-27 
days and 28+ days. As a result those went to the physician in week 2 (7-13 days) could 
not have coughed less than 7 days. These simulated data do not take into account any 
cases who sought care prior to coughing, or those who did not receive antibiotics. This 
process assumes that the use of antibiotics has no effect on cough duration.
6,11
  
Stratifying on a variable within the causal pathway between time of expose and outcome 
can induce bias.
19
 In our data, healthcare seeking behavior is affected by both the severity 
and duration of disease. Therefore, stratifying on when an individual first sought care 
(week of antibiotic prescription) could bias the association between exposures such as 
age, cough attributes, and epidemiologic linkage or outbreak status and the outcome, 
reporting of a cough compliant with the clinical case definition.  For this reason, analyses 




3.2.4. Predictors of adequate cough duration report 
To evaluate whether the case’s medical timeline and the association with other known 
cases varied over the study period, a table that annually summarized the raw data was 
examined. Records that did not report cough duration were excluded.  
Next, logistic regression was run to determine variables associated with accurate 
reporting of the requisite 14-day cough, the minimum in the CDC’s clinical case 
definition. Insufficient cough duration was termed a cough duration failure, as the case 
failed to meet the clinical case definition. This duration failure may be a result of the 
reporting process, and may not accurately represent the case history. Analysis was 
restricted to cases who sought care before 14 days of cough, and for whom duration of 
cough was reported. Those who sought care on or after 14 days were examined to 
estimate the overall accuracy of the reported duration; they were excluded from the 
predictors of adequate reporting since they by definition met the cough criteria.  
All the predictors of cough length reporting were examined in univariate logistic 
regression to determine the strength of the association. After identifying all significant 
associations, numeric variables were examined for collinearity, which occurs when two 




The collinear variables having a condition index over 30 were excluded from the model 
creation process. The model was constructed based on the remaining variables using a 
two-stage backward model selection. The initial stage included all significant, non-
collinear individual predictors, which were selected for removal in reverse order of 
significance. The second stage examined potential interactions of age with the remaining 
individual predictors. The final decision on whether to include a predictor or interaction 
at either level was based on model fit criteria as quantified by the lowest AIC value. All 
analyses were conducted using SAS version 9.2 (Cary, NC). 
3.3. Results 
The distribution of reported cases varied widely by year and age group (Figure 3.1). Most 
notably, there was a trend toward increased reporting of pertussis in adolescents and 
adults, both in absolute numbers and in overall proportion. Infants however bear the 
highest incidence of disease. Table 3.3 describes the characteristics of health seeking 
behaviors and diagnostic patterns in Michigan during this 11 year period. No temporal 
patterns were obvious for length of cough (ranging from a mean of 28.0 to 38.7 days), 
time to antibiotic treatment (14.5-20.5 days) or time to PCR testing (15.0-26.0 days). 
PCR testing was positive in more than 90% of cases reporting testing in all but one year. 
Less than a quarter of cases were considered "outbreak" associated in most years, except 
in both 2001 and 2006, when more than 40% of cases were considered outbreak 
associated. In the last two years (2009, 2010) the proportion of cases associated with a 
defined outbreak were exceedingly low (Table 3.3). There were no clear patterns 
associated with cases reported as epidemiologically linked, not even in the last two years 
with many reported cases.  The years 2004, 2006, and 2010 had atypically short times 
from cough onset to initial healthcare visit (14.9, 14.7 and 14.5 days), which was 
paralleled with a slightly shorter mean duration of cough.  
Significantly more cases met the CDC case definition before 2006 than after, 50.2% and 
43.9% respectively (unpaired T-test=3.7, df =4788, p<.001) this is after the large 
outbreaks began and vaccination recommendations for adolescents and adults were 
instituted. Records where the individual was still coughing at the final healthcare visit, a 




or outbreaks in chi-squared testing. Some individual years did show an association 
between a higher proportion of ongoing cough and outbreak status, including 2000, 2003 
and 2005. However, in 2010 this association was reversed and outbreak cases were 
associated with a lower proportion of cases ongoing cough than in their non-outbreak 
counterparts.  This ongoing cough was associated with age in those in reported outbreak 
settings, due to 1-4 year olds being twice as likely as all other ages (16%) to be still 
coughing. 
Clarithromycin/Azithromycin was the most frequently prescribed antibiotic (69.8%) 
while another 14.0% of cases received Erythromycin (Table 3.2), all macrolides. The 
proportion of cases each year treated with Clarithromycin/Azithromycin increased over 
the study period, and a slight decline was evident in treatment with Erythromycin (Table 
3.3).  
The proportion of individuals reporting the clinical characteristics of illness increased 
over the first two weeks of cough, after which they did remained similar (Table 3.4). The 
most frequent clinical characteristic reported was paroxysms, which is similar to other 
surveillance studies.
12
 Epidemiologic linkage occurred primarily with those seeking 
medical care in the first week of cough. Classification of cases as part of an outbreak was 
not reported frequently (3.2%) in those who received antibiotics prophylactically, but was 
greater in those diagnosed after they had already begun coughing. There was no 
association with history of vaccination. 
Older patients exhibited a broader distribution of cough duration, and antibiotic 
prescription occurred later after cough onset (Figure 3.2). Only among children did the 
mean time to initiation of antibiotic therapy occur just prior to 14 days (13.3 days) (data 
not shown). Further investigation into the medical care timeline indicates that antibiotic 
prescription and laboratory testing were frequently conducted concurrently at 11-12 days, 
with diagnosis occurring about three days later (Table 3.4). Of these data only 11.3% did 
not have a cough attribute on file, 10.6% among infants and about 15% in all older age 
groups. (Data not shown.) The more delayed the initial visit and first antibiotic 
prescription, the longer the average cough duration and the more likely it was that cases 




duration by week of initial antibiotic prescription relative to cough onset showed an 
increasing cough duration when the initial healthcare visit was delayed, this was 
significant in a Kaplan-Meier comparison (P< 0.0001)(data not shown).  
However, those who took antibiotics prophylactically, in week 0 reported cough lengths 
that averaged longer than those who took antibiotics in the first two weeks of cough 
(Figure 3.2). This is also seen in Table 3.4,where the week 0 patients (N=251)  reported 
cough duration was similar to those who took antibiotics in the second week of cough.  
The other descriptor variables of this prophylactic group matched those of the other 
groups but without a clear pattern. Some characteristics, including use of a macrolide 
antibiotic, clinical attributes, and lab testing, the prophylactically treated group had the 
lowest reported frequency. In other instances like the diagnostic timeline these 
prophylactic cases were similar to those who sought care in the first week after cough 
onset.  
Had earlier antibiotic treatment resulted in shorter cough duration, then one would expect 
that those who received antibiotics prior to cough onset would have the shortest overall 
cough duration. This is not seen and leads us to suspect that the apparently longer cough 
duration observed among cases with a delayed initial healthcare visit may be the result of 
bias in data collection. If antibiotics have no effect on cough then those who sought care 
prior to cough onset 
11
 or those who did not use antibiotics 
1
 (N=397), would provide an 
unbiased subset of the database if the entire the cough duration was reported.  However, 
among these potentially unbiased cases, only 171 (43.1%) reported any cough duration, 
and three-quarters of them were still coughing at the final interview. As these portions of 
data were not robust enough to support additional analysis a theoretical simulation was 
conducted comparing the average reported cough duration according to the week of the 
initial healthcare visit. 
The log-normal simulated distribution was left-truncated over five time periods, 
representing the delay of seeking medical attention, <7 days, 7-13 days, 14-20 days, 21-
27 days and 28+ days. The means were calculated for each of the four truncations 24.9, 
25.8, 31.0, 38.0 and 45.3 days; the proportion of cases observed according to timing in 




care seeking bias results in longer mean cough duration with each successive week. An 
increase of 1 day of cough occurs between weeks 1 and 2, 5 days between weeks 2 and 3, 
and 7 days between successive weeks. This could mistakenly be interpreted as an effect 
of antibiotic therapy, however this comparison was made from data simulated under no 
treatment effect; it is therefore a direct result of the case exclusion bias. This case 
exclusion bias as illustrated through truncation describes the observed difference in 
cough duration seen in the actual MDCH data over the first five weeks when more than 
three-quarter of cases sought medical care (24.7, 25.7, 30.6, 34.8, and 58.3 days mean 
cough duration).  
At the exclusion of antibiotic timing, the multivariable logistic regression found records 
with any one of the three confirmatory criteria, i.e. culture positive, PCR positive, or 
epidemiologic linkage, had increased odds of inadequate cough reporting (Table 3.5). 
This final statistical model contained only those records for which cough duration was 
numerically reported (N=1,755, 16 % reported cough failure). Because those who sought 
care after 14 days would, by definition, meet the criterion, they were excluded from this 
analysis. In addition, 18 of these 1,448 records reported insufficient cough values, 
representing reporting accuracy of 98.7%. A sensitivity analysis that included the records 
missing cough duration as insufficiently reported cough produced results that were 
comparable to the model presented (data not shown). The results indicate better odds of 
reporting a 14 day cough among, school-aged children, those presenting with post-tussive 
vomiting or paroxysms, and those initially treated with a beta-lactam class antibiotic. 
Positive lab testing by culture or PCR, as well as an indication of epidemiologic linkage, 
was associated with failure to report sufficient cough duration. 
3.4. Discussion 
The perceptions of pertussis have changed dramatically since 2000 among both 
healthcare providers and the general U.S. populace, now that pertussis is recognized as a 
contemporary public health issue. This has occurred primarily as a result of nation-wide 
media attention garnered from a large outbreak in 2004, the 2010 outbreak which resulted 
in 10 infant deaths in the state of California, and 2012 outbreaks in Washington and 
Minnesota.
20




reported to have received earlier treatment, and an increased proportion had PCR testing, 
as compared with non-outbreak years. This increase in PCR testing is critical as these 
cases fell under a new (1997) surveillance reporting category (Table 3.1 #3). Results in 
chapter 2 indicated that these cases were frequently misreported, with as many as 35% 
having inadequate cough length information. Our study found that all of the confirmation 
criteria (culture, PCR, epidemiologic linkage) were associated with increased odds of 
inadequate cough duration and subsequent failure to meet the clinical case definition. 
Since the study began a change over from prescription of erythromycin to azithromycin 
was evident, after 2005 according to the CDC recommendation given their comparable 
effectiveness, but the lower side-effect profile, shorter course of therapy, and higher 
completion rates of patients taking azithromycin.
9
 Individuals taking antibiotics 
prophylactically, before their cough began, required at least a second physical visit to a 
healthcare provider to verify illness, as cases are only reportable after diagnosis. These 
cases report a lower frequency of cough attributes because the second visit usually occurs 
early in the first week of cough, and the attributes may appear as late as the second week 
of coughing. There is also a possibility that early antibiotic use led to a decrease in 
disease severity as manifested in the clinical presentation, if antibiotics were able to 
curtail the extent of cellular damage. 
Our simulated data examination on the effects of the case exclusion bias that occurs in all 
surveillance data, ignored any effect of antibiotics on cough length, and yielded a 13 days 
difference in reported cough length between those who received antibiotics in the first 
week since cough onset and those who waited until the third week of cough. This bias-
based difference in cough duration is similar to that observed in the MDCH data after 
stratifying on week of antibiotics and suggests that antibiotics are not the cause of the 
shorter cough duration associated with earlier healthcare visits which coincides with 
initial antibiotic treatment. Since the cough is a physical response to overcome extensive 
cellular damage caused by the bacteria, and these ciliated epithelial cells have a long 
lifespan with a reported half-life of six months, the cough duration may depend more on 






While our simulation was based on the mean cough duration reported in the MDCH data 
(26.8 days), we found that 80% of all reported cases had ongoing cough at the final 
healthcare visit. Therefore, our analysis was based on incomplete cough data. Another 
study which followed pertussis cases to the end of their cough, 80% of cases had finished 
coughing after 60 days, more than twice the surveillance reported cough duration, which 
suggests that our surveillance cases are followed for just over a month.
12
 This length of 
follow-up should be sufficient for most case management and even outbreak 
investigations; however statements pertaining to cough length and antibiotic effectiveness 
must be based on complete follow-up of a complete case cohort. While these bias effects 
should not be evident among either those who sought care prior to cough onset,
11
 or those 
who did not use antibiotics,
1
 these records were small in number and also plagued by the 
“still coughing” designation, so it was not possible to verify these conclusions in this 
subset of the MDCH data.  
We recognize that missing data may have affected our findings, and probably reflects 
fluctuating accuracy and completeness associated with changing resources available to a 
local health department. Reporting and outbreak investigative capacity varies over time 
within a given health department, secondary to changes in workforce priority, resource 
availability and a number of other factors.
22,23
 These limitations are common to all 
surveillance data. We assume that this was random and would have reduced the strength 
of associations that were observed. 
As opposed to the incomplete cough duration reported in the surveillance data, there is 
also a high proportion of inadequate reporting, to the point where the reported case does 
not mean the surveillance case definition. The odds of such inadequate reporting of cough 
duration, reporting less than 14 days of cough, were more frequent when a confirmatory 
indicator was present (i.e. culture or PCR positive or epidemiologic linkage). The current 
case definition has no specified duration of cough for those cases confirmed by positive 
culture (OR: 2.1, 95%CI(1.4 – 3.2)). This finding suggests that there is a gross 
misinterpretation of the confirmatory criteria as sufficient in and of themselves to merit 
confirmatory status. However, the presence of a confirmatory indicator substantiates but 




those confirmed by either PCR or epidemiologic linkage and requires at least 14 days of 
cough with a reported cough attribute.  
This misunderstanding can be mitigated by streamlining the case definition so both 
confirmatory lab tests confirm cases using a single case definition formula. It seems 
reasonable that if a case is laboratory positive, the cough of any length must be 
accompanied by at least one cough attribute (i.e. whooping, paroxysms, or post-tussive 
vomiting). This simplification should clarify the role of laboratory confirmation in 
pertussis surveillance, and so should improve the accuracy of the reported cases in such a 
way that a great proportion will meet the case definition. 
All cases without a positive laboratory test should continue to be required to meet the 
current clinical case definition, including the 14 day cough duration. A small proportion 
of these cases also identified as epidemiologically linked could also be given a confirmed 
status but only after meeting the clinical case definition. This later recommendation is 
consistent with the US CDC’s case definition for probable cases and cases confirmed by 
epidemiologic linkage since at least 1990.
24
 However some physicians were not aware 
that probable cases (Table 3.1 #1),
25
 and this study has clearly indicated a 
misunderstanding of the role of confirmatory criteria with regard to the case definition. 
These recommendations would allow confirmation of 376 (7.8%)  additional reported 
cases in the data. It did not affect those confirmed by epidemiologic linkage or probable 
case status, and would improve the confirmation rate among infants by 12% and 
sequentially fewer cases as age increases to 5% among adults. The sensitivity of the new 
recommendations among those currently confirmed by culture is 89.7%.  The 44 culture 
confirmed cases without an attribute are evenly spread across the age groups, this may 
occur as a result of the current case definition which does not require any attributes when 
confirmed by culture. Bortolussi et al reported that among those less than two years of 
age a cough attribute was present in 80% by 7 days and in 97% coughing 14 days.
12
 
Therefore most infants would be confirmable under the new recommendations. 
In addition to streamlining the case definition regarding laboratory positive case 
confirmation, a standardized protocol for PCR testing of pertussis should be created to 




epidemiologic linkage and outbreak association status, as our study suggests that this 
information is reported in only 20% of cases. These categorizations are increasingly 
important with the upsurge of pertussis cases and statewide outbreaks. Having a clearer 
understanding of how cases are associated can be used to improve outbreak control 
strategies, by informing the targeting of vaccination campaigns and guiding case 




Table 05 Pertussis surveillance reporting criteria used during the study, as published by 
the Centers for Disease Control and Prevention, based on the 1997 case definition which 
is compatible with the 2010 edition. These definitions are established by and report.
2
 
1.) Probable Case (a clinical case) defined as: 
–  Cough ≥ 14 days  
WITH 
–  One of the following: paroxysms, whoop, or post-tussive vomiting 
 
2.) Confirmed Case requires an epidemiologic link, and the clinical case definition 
 
3.) Confirmed Case requires a positive PCR test, and the clinical case definition. 
 
4.) Confirmed Case requires a positive bacterial culture and a cough. 
 
5.) Outbreak Case must occur in an outbreak setting and coughs for 14 days or more.  
 
 
Table 3.6 The recoding of antibiotic information for reported pertussis case records in 
Michigan, 2000-2010 , to standardize additional information included as free form text in 
the original dataset (N=4800) 
MDCH 













(incl. pediazol, ilosone) 





2772 2867 3039 
3,692 
5 Amoxicillin 285 289 292  
7 Penicillin 4 4 4 β-lactamase 
8 Ampicillin 14 16 17 431 
10 Augmentin 46 50 49  
11 Ceclor 6 8 11  









33 38 43 
312 
6 Other 104 110 134  
9 Unknown 89 100 96  
- Missing 747 591 365 365 
* 
These are the records coded as received from the Michigan Department of Community Health. 
†
This is the recode of the free-form text responses for the first and second antibiotic variables. 
‡
 Classification of the previous data according to antibiotic class. First generation cephalosporins 







Table 3.7 Trends in reported data, describing the diagnostic timeline and the prevalence of case management 
characteristics among the probable and confirmed cases of pertussis in Michigan 2000 – 2010 (N=4790) 
Year 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 
Total reported cases 127 148 61 139 313 334 631 270 347 918 1502 
Illness timeline (mean)            
Cough duration (days) 36.1 38.7 36.3 34.4 30.4 32.5 28.0 31.5 32.8 31.3 29.0 
Days to Antibiotic 18.6 20.5 20.2 16.5 14.9 16.3 14.7 17.4 17.1 16.0 14.5 
Days to PCR test 26.0 16.6 18.0 16.4 16.6 16.9 16.1 19.0 15.8 16.1 15.0 
Prevalence (%) of characteristic among those with information:    
Erythromycin  43.3 58.8 41.0 39.6 29.7 28.1 12.5 11.5 10.7 5.8 2.9 
Other Macrolide  15.0 9.5 21.3 30.9 39.6 53.9 68.1 63.7 59.7 70.2 78.3 
PCR positive  75.0 100.0 90.9 93.8 90.7 90.5 95.5 91.5 95.9 97.6 97.9 
Outbreak 35.4 55.4 34.4 36.0 21.4 16.2 46.8 13.3 10.4 2.9 1.9 








Table 3.8 Descriptive statistics of time patterns of symptom onset, diagnosis, and treatment based on pertussis case records with 
reported cough from Michigan, 2000-2010. 
    















Male (%) 4,604 44.0  43.0 43.1 43.2 45.0 
Age in years (median, IQR) 4,569 10.7 (2.8-33.6) 12.7 10.4 9.7 11.0 
Days to  1
st
 antibiotic (median, IQR) †
 
4,069 11 (6-20) -6 3 9 22 
Days to PCR (median, IQR) †
 
2,135 12 (7-21) 3.5 4 9 21 
Days to diagnosis (median, IQR) †
 
2,819 16 (9-26) 8.5 7 12 24 
Macrolide Antibiotic (%) 4,412 83.0  78.8 79.9 84.8 87.7 
Coughing at final interview (%) 4,004 79.9  75.4 77.8 83.7 81.1 
Cough duration days (final) 586 25 (15 – 41) 22 15.5 18 35 
Cough duration days (still coughing) 2,708 26 (18 – 40) 25 19 21 34 
Any cough attribute (%) 4,610 88.7  74.5 85.9 91.7 91.6 
Whooping (%) 4,610 35.2  32.0 39.1 41.1 39.4 
Paroxysms (%) 4,610 82.7  77.7 83.6 88.7 88.8 
Post-tussive vomiting (%) 4,610 49.2  48.9 46.8 52.7 54.6 
Apnea (%) 4,610 33.5  27.5 32.4 36.2 34.0 
Laboratory positive test (%) 4,610 53.2  48.6 56.8 62.5 50.2 
Culture (%) 4,610 10.2  8.4 11.1 11.0 9.8 
PCR (%) 4,610 43.9  41.4 47.0 52.2 41.2 
Epidemiologic linkage (%) 4,610 19.2  18.7 22.8 17.8 17.5 
Outbreak (%) 4,610 16.1  3.2 14.13 17.0 17.9 
Vaccination Record (%) 4,610 56.7  75.9 72.48 70.7 74.3 
* 
These cases had their first medical visit prior to the onset of cough, and received antibiotics prophylactically.
 




Table 3.9 The odds of cases of pertussis in Michigan, 2000-2010 being reported 
with insufficient cough duration for confirmation of pertussis, according to the CDC 
guidelines. 
Parameter Odds Ratio 95% CI 
Age Group   
     Child (0-4yrs) -Reference-  
     School-aged(5-19 yrs) 0.429 (0.315 – 0.585) 
     Adult(20+yrs) 0.412 (0.292 – 0.582) 
Post-tussive vomiting 0.585 (0.442 – 0.775) 
Paroxysms  0.387 (0.287 – 0.523) 
Whooping 0.721 (0.542 – 0.960) 
Cough cessation 0.745 (0.545 – 1.017) 
Culture positive 2.087 (1.357 – 3.211) 
PCR positive 2.094 (1.571 – 2.791) 
Epidemiologic linkage 1.440 (1.059 – 1.958) 
Antibiotic    
     Macrolides -Reference-  
     Beta-lactams 0.189 (0.189 – 0.608) 












Figure 3.4 The distribution of reported cough duration by age-group and the week 
antibiotics were first prescribed relative to cough onset, where cough was less than 150 
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Chapter 4  
Population and County Risk Factors of Pertussis Incidence 
 in the U.S.A., 1991-2008 
4.1.  Introduction  
Pertussis, or whooping cough, is a prolonged cough illness that may result in 
hospitalization and mortality in very young children.  While disease is experienced, 
diagnosed, and reported at the individual level, the factors leading to illness should be 
considered in a broader socio-cultural environment that contributes to risk; including 
social networks, health behaviors, and financial resources. These characteristics describe 
the nature of the local community and represent the greater context in which the 
individual moves and is potentially exposed to disease. The importance of the socio-
structural construct is often discounted because medicine is evidence driven and practiced 
at the individual level. However, the intangible beliefs and perceptions of health are 
molded by the individual’s friendships, past experience and what he recognizes as the 
norm in his community. 
 The field of social epidemiology characterizes these socio-structural factors which 
impact the distribution of health and disease and explores the mechanism of influence on 
both individual and population health.
1
 Social epidemiology generally explores complex 
health outcomes of insidious onset, frequently associated with aging including obesity, 
mental health, and mortality. Vaccine preventable diseases like pertussis differ in that 
they: primarily affect pediatric populations; have a specific biological cause which is 
preventable; had a drastic decline of incidence secondary to introduction of a vaccine. 
The social epidemiologic approach is useful perspective as health behaviors are socially 
patterned derived from the physical and social environment of the individual. 
There has been very little work in the field of social epidemiology directed at the study of 
vaccine preventable diseases; although a recent study examined community risk factors 






Some individual-level disease investigations have suggested potential community-level 
characteristics of disease risk, such as family size, age distribution, and commuting. 
3,4
Community-level characteristics such as income inequality, unemployment, and the 
proportion of the workforce commuting, each describe a group of people among whom 
the case resides. As a communicable disease of exclusively human origins, pertussis 
infection would be strongly affected by the specifics of the local socio-cultural 
environment.
4,5
 This plays out not only in the physical interactions and resources but also 
in the exchange of health beliefs and behaviors, that flow across social networks and 
establish social cultural. For a vaccine preventable disease (VPD), like pertussis, these 
environmental factors mold both the views on immunizations and healthcare preferences. 
As pertussis is primarily a disease of the young, most cases are passive recipients of the 
socio-cultural environment as filtered through the choices of their parents or guardians. 
The social epidemiology perspective can develop our understanding of pertussis risk 
factors by through an examination of community-level, societal and environmental 
influences that result in a high risk setting. In this study, we examine three broad 
categories of population-level risk factors and their effects on pertussis incidence: factors 
of disease acquisition, healthcare access, and poverty. 
4.1.1. Disease acquisition 
An individual’s potential exposures to a pathogen are a combined byproduct of the 
social-network structure of the community, both internally and with other 
communities.
6
In a consideration of county-level predictors for risk of pertussis exposure, 
there are two components to be evaluated; disease introduction and disease transmission. 
The more frequently people enter and exit a geographic area, such as a county, the greater 
the risk that the bacteria is introduced into the resident population.
7
 At the county level, 
this introduction risk will be analyzed though estimates of community connectivity, 
assuming the more highly connected counties have more frequent importation of 
infection. This is captured in factors such as the proportion of the workforce commuting 
out of county and the connection to local urban or metropolitan areas, since disease tends 






The within-community mixing relates directly to transmission risk, and describes the risk 
of exposure to B. pertussis at the community level. Factors such as family-size, group 
housing, household-level crowding, and county-level population density all quantify 
daily interaction patterns among the population.
4,6
These measures are somewhat crude 
but the intent, nonetheless, is to summarize routine personal interactions by quantifying 
the county population who live in high contact settings. The age composition of the 
population is included under this heading, as pertussis tends to be more distinctively 
symptomatic, and serious among young children, with less specific symptoms occurring 
in older and vaccinated individuals, making diagnosis more difficult.
9
  
4.1.2. Healthcare access 
Healthcare access is important to both pertussis prevention and diagnosis. Access can be 
considered from two different but equally viable perspectives. The first is the availability 
of clinical or healthcare services; the second is the ability or willingness to use said 
services. The availability of healthcare services includes any interaction where an 
individual has access to preventive immunization or for the clinical diagnosis of pertussis 
to be made. The ability to use services can be impeded by lack of health insurance, 
cultural barriers like language and ethnicity, and physical barriers such as distance or lack 
of transportation. 
Healthcare services are most effective in impacting pertussis epidemiology through 
provision of clinical preventive services like routine vaccination of young children. The 
recommended vaccination schedule for pertussis requires multiple visits to a healthcare 
provider at 2, 4, 6 and 12-18 months of age. Additional boosters are recommended at 4-6 
years and again at 11-12 years.
10
 Immunization coverage studies have shown that 
immunization rates are highest in areas where there are more pediatricians per capita.
2
 
The age, training and specialties of local physicians might affect patterns.their views on 
the importance of preventive services as well as diagnostic  
Utilization of services can be affected by a number of factors including a person’s health 
insurance status and cultural barriers. Cultural incompatibility between an individual and 
those providing the health services is an important aspect of healthcare utilization, 




inaccessibility. For example, reluctance to use conventional healthcare services can be 
due to wariness, cultural values, stigma, or personal beliefs.
11
 This could be measured as 
the proportion of a population who are considered to be outside of the mainstream 
culture, minorities (proportion non-white), under-educated, foreign-born, or non-English 
speakers. In the long run, any reluctance to utilize healthcare services, whether due to 
financial constraints or social convention, has the potential to weaken the health profile of 
the community. As surveillance data originates through providers of conventional 
medical practices, the data represents those who are willing and able to seek care from 
these sources. Those who choose to use alternative medicinal practices are both more 
likely to be unvaccinated; 
12
 if there is critical mass of like-mindedness in a given area 
they can facilitate ongoing transmission.  
4.1.3. Health & Economic Risk Factors 
While access and use of conventional healthcare resources are important factors to 
consider when assessing community risk for pertussis, other secondary factors can affect 
pertussis incidence as well. For example, healthcare use patterns may be influenced by 
individual factors, relating to the personal resources of the individual or household-level 
constraints, such as finances, and transportation. The physical proximity of healthcare 
resources such as a hospital, clinic or doctor’s office, where clinical diagnoses and care 
occur, vary by residence, and is tied to factors such as population density, rurality, 
financial resources of residents, and the resulting fiscal solvency of the local healthcare 
enterprise. While some of these factors are related to the affluence of the community, 
special governmental programs attempt to address these disadvantages and allocate 
resources to mitigate the effects of poverty, at both the household and community levels. 
Poverty, wealth inequality, and poor child health were considered factors that may 
increase disease risk in local communities. These descriptive measures can be quantified 
at the county level and used to describe the relative degree of disadvantage present in the 
county. In addition to poverty measures, other socio-economic factors, including 
unemployment, lack of health insurance, or the proportion of single-parent households 
diminish resources available to people and often occur concurrently, with clustering of 
these factors occurring within communities. In general, communities with a higher 




incidence of pertussis. This study examined population composition and distribution, 
healthcare availability, cultural barriers and poverty quantified at the county level, as 
indicators of increased risked of pertussis. 
4.2. Materials and Methods 
4.2.1.  Pertussis Case Data 
The data for this analysis were provided by the United States Centers for Disease Control 
and Prevention (CDC) as all pertussis cases reported from physicians and hospitals, 
between 1 January, 1991 and 31 December, 2008. The CDC has designated pertussis and 
many other diseases as nationally notifiable. The legal basis for formally requiring the 
report of health conditions to public health authority is under state jurisdiction, and all 50 
states, the 6 territories, and Washington DC explicitly require the reporting of pertussis.
13 
The states, in turn, send reported pertussis cases to the CDC, and these case reports 
include identifying demographic characteristics and the county and state of case 
residence.  
The original data set contained 167,122 records submitted as either probable (clinical 
cases) or confirmed (cases with laboratory evidence) pertussis case. Of these records, 163 
were excluded as multiple cases were combined in a single entry. Another 970 records 
could not be assigned an age, and 2,863 more were not assigned to a specific county, 
although a valid state of residence was provided. The remaining 163,554 cases were 
analyzed by age and county but collapsed over time. This was done for statistical 
purposes to minimize the numbers of zero reports in the data. Of the 3,143 U.S. counties 
13.6% (N=427) did not report any pertussis cases for the entire study period; they were 
included in the analysis. Counties without reported cases were distributed across the 
country, although 75% of these counties had a population of less than 260,000 people. 
4.2.2.  Demographic and Risk Factor Data 
Residence of cases was provided as county and state which constitutes the finest spatial 
resolution in the analysis. County-level demographic data were collected primarily from 
federal sources and represent standardized values for all U.S. counties. Population data 




data also provided household-based information summarized at the county level. The 
county-level predictors are the same for all age groups within a county. 
County-level predictor variables were gathered from several sources, but primarily from 
the Health Resources and Services Administration’s (HRSA) Area Health Resource File. 
This database contained healthcare availability factors, and data on cultural barriers, 
poverty and introduction risk. The variable of "Interstate Miles", representing risk of B. 
pertussis introduction, was created from spatial aggregation methods (available in 
ArcGIS version 9.2, Redlands, CA), using the road system base layer in ArcGIS. To 
facilitate comparisons, predictor variables were grouped into three broad categories 
involving bacterial transmission, healthcare barriers and poor child health. A 
disadvantaged county is one that has a higher proportion of healthcare barriers or poor 
child health. 
4.2.3. Analysis 
The county-level association of each predictor variable with the incidence of pertussis 
was first examined using standard regression methods for bivariate associations. Then, a 
negative binomial regression model was developed in which the count of the number of 
cases per age-group within each county was the outcome, with an offset being the log of 
the population for each age-group. The negative binomial distribution is appropriate for 
count data in situations where the variance is greater than that allowed for a Poisson 
distribution. This was done using generalized estimating equation (GEE) methods, which 
created a population average model where the average effect of each predictor is 
estimated across all counties. Clustering of county values was adjusted for by specifying 
an exchangeable correlation structure for the repeated measures (i.e., the count for each 
age group), and using the robust estimates of standard error. By taking into account the 
correlation among observations in the same county, the sandwich-type estimates of 
standard errors adjust the model-specific standard errors and are consistent, even in the 
presence of a mis-specified covariance structure.
14
The outcome was the aggregated 17-
year count of reported pertussis cases by county for each age-group: infants <1 year, pre-




county size using the log of the age-specific county population, due to the log-based link 
function. 
County-level predictors were grouped into the following categories: interpersonal 
proximity and contact, pathogen introduction, healthcare availability, cultural barriers to 
healthcare, poverty and inequality, and poor child health. Within each grouping the 
individual variables were run in a bivariate GLM model to determine the explanatory 
power of the predictor, adjusting for age and controlling for clustering. Significant 
predictors (p < 0.10) from the bivariate analyses were entered into a single model and 
collinearity of the predictors was assessed. Where collinearity was found, as indicated by 
an Eigenvalue and condition index of >30,
15
 these variables were removed from further 
analysis, and collinearity was re-assessed until the maximum condition index did not 
exceed 30. A category-specific model was then fit with each predictor, using a backward 
step-wise model building approach, including all significant, non-collinear predictors. 
Variables appearing as non-significant according to type-III tests were considered for 
removal from the model. Non-significant variables were retained when the model fit was 
improved by their retention, as determined by the QIC (Quasilikelihood under the 
Independence model Criterion) statistic, the goodness of fit criteria for GEE models.  
The significant predictors for each category were then combined into an overall model, 
and assessed for correlation and then collinearity. Remaining variables were reviewed in 
a similar backward step-wise manner. All modeling was conducted using SAS version 
9.3 (Cary, NC).  
4.3.  Results 
Risk-factors for pertussis infection were identified under three broad categorical 
associations: pathogen transmission (1a,1b), healthcare barriers(2a-c) and poor child 
health(3). Initial bivariate analysis indicated that many of the significant associations 
involved an inverse relationship between indicators of disadvantage and pertussis 
incidence (Table 4.1).  A positive association was seen among the pathogen introduction 
variables quantifying urbanicity, as well as the barriers of age, housing stress and the per 




as barriers to receiving healthcare, behaved in a consistent manner which seemingly 
contradicts the hypothesis that disadvantage results in more disease. 
To explore the incongruent findings between the two classes within the pathogen 
transmission variables, risk of introduction and risk of contact, population mobility and 
density were selected as representative variables for stratification. This assessment 
attempted to determine whether these aspects of urbanization could account for the 
discordance, as urban areas are known to have a lower incidence of pertussis. Table 4.2 
separated the counties according to the two classes of variables within pathogen 
transmission, and evaluated whether pertussis incidence showed a pattern indicative of 
either or both population density (above or below average) or the mobility of the county 
(presence or absence of an interstate highway within the county limits). The four columns 
on the right show a gradient from the more densely populated and connected counties, to 
more sparsely populated, less dense counties. The orientation of the four categorical 
columns is arbitrary and the current form was selected to parallel the visual decline in 
population density. Two-tailed Satterthwaite T-tests for unequal variances were 
conducted to determine if significant differences occurred across either population 
density or presence of an interstate. The association between each variable and pertussis 
incidence has been shown previously (Table 4.1).  
Most of the predictors showed significant differences across both aspects of pathogen 
transmission, population density and mixing. The only other variable, that paralleled 
density, and decreased across all four groups was the rate of licensed medical personnel 
(MD and RN) per 1,000 persons. A few variables exhibited trends that increased while 
population density declined including: median age, the proportions of children in poverty, 
and the lack of health insurance.  Only housing stress and the proportion of minorities 
showed a significant differences in pertussis incidence when an interstate was present or 
absent, but was not associated with density. The inverse, an observed discrepancy in 
pertussis incidence observed in high verses low density counties but not seen in the 
presence/absence of an interstate, was seen for crowding, low birthweight births, and 




areas (Below average density=2.06, above average density=1.71 average age-adjusted, 
annual incidence per million persons). 
In the national multivariable statistical model, as with the bivariate associations, most 
predictors were associated with decreased pertussis incidence (Table 4.3). Only two 
remaining variables were positively associated with pertussis incidence; the per capita 
rate of licensed medical personnel and housing stress, the latter of which was marginally 
non-significant. The per capita rate of licensed medical personnel shows inverted 
associations with both child poverty and those lacking health insurance (Table 4.2), 
suggesting this metric loosely mirrors affluence, therefore its absence marks 
disadvantage. Lower per capita rates of licensed medical personnel are associated with 
decreased incidence, consistent with the other healthcare barriers and indicators of 
disadvantage. The variables for pathogen transmission, population density and mixing 
(the commuting workforce) as well as adverse child-health outcomes were also 
significantly associated with lower pertussis incidence. 
Stratifications of the national model on the presence of an interstate within county limits 
was conducted to determine whether there were any significant differences in risk factors 
bases on connectivity and isolation of the communities (Table 4.3).  The interstate-free, 
isolated counties having theoretically fewer opportunities for pathogen introduction were 
similar to the national model. Counties with interstates showed a significantly higher 
incidence of pertussis associated with housing stress, defined by the Economic Research 
Council as the proportion of houses with at least one of the following characteristics: 
incomplete plumbing, incomplete kitchen facilities, renter or owner cost >30 % of 
household income, or >1 person per room.  
To determine whether these associations were consistent throughout the study period 
with the upsurge of cases and significant changes in diagnostic measures, the national 
model was run on subsets of the data, defined as follows: prior to 1997 when then case 
definition did not include PCR, 1998 through 2003 as PCR was being incorporated into 
diagnostic practice, and 2004 or later when large scale outbreaks began occurring. There 
were no substantial differences among these period-specific models, which were similar 




Because healthcare outcomes and unhealthy conditions are known to vary regionally 
throughout the United States, the model was stratified on the four census regions (Table 
4.4). These individual, region-specific models did not vary significantly from the base 
model, except for the proportion of the population with very low education in the 
Midwest, which not only changed direction but became a risk factor for greater pertussis 
incidence.  This finding resulted in a more detailed investigation of populations known to 
have less than a high school education. We focused on the distribution of the Amish 
population as they are known to complete schooling after the eighth grade, reside 
primarily in rural farm economy areas associated with the Midwest, and have been 
reliably enumerated by county in the 2010 Religious Congregations and Membership 
Study (www.RCMS2010.org), which takes a census of a wide range of religious 
affiliations.  
“Amish counties” were operationalized as counties where the Amish congregation was 
greater than 1,000 members or where the Amish population comprised more than 5% of 
the country population. Two-thirds of all Amish counties were found in the Midwest 
region, though large populations are also found in adjacent states (i.e. Pennsylvania, New 
York and Kentucky). In states having at least one Amish county, Amish counties have an 
age-adjusted average annual incidence of 2.91 per 100,000 county residents while non-
Amish counties report an average 1.74 incidence (Satterthwaite T-test p<0.01). Though 
there is not a significant difference within any of the three regions based on these states, 
excluding the western states. Nor is there a significant difference in pertussis incidence 
when Amish counties are re-defined as comprising a minimal 1% of the county 
population or greater than 1000 Amish members, in states with a minimum of five Amish 
counties. An average discrepancy between the Amish and non-Amish counties was a 
slightly elevated 0.41 cases per million in Amish counties (Satterthwaite T-test (unequal 
variances) p=0.13)). This risk difference may drive the increased pertussis incidence 
associated with under-education in the Midwestern region, but not elsewhere in the U.S. 
4.4. Discussion 
This county-level analysis of risk factors associated with pertussis in the U.S. produced 




reported pertussis. These associations were consistent for variables of increasing 
disadvantage identified by all three categorical areas: pathogen transmission, healthcare 
barriers and poor child-health outcomes. The directionality was strong and remained 
constant throughout the U.S., across time, and in counties both with and without 
interstate highways. Of particular interest was the decreased incidence of reported 
pertussis associated with lower population density and the greater proportion of the 
workforce commuting to other counties, and the increased risk of pertussis in the 
Midwest among those counties with a greater proportion of the population lacking a high 
school education. 
The pathogen transmission factor, population density continued to be highly significant in 
most models, and was inversely associated with the incidence of pertussis. This 
association is historically consistent as far back as the 1910s.
16-18
 Historic findings were 
attributed to delayed exposure in non-urban settings based on a comparison of infectious 
disease incidence rates between urban and rural military recruits in World War I and 
again in World War II.
18
 While the magnitude of the observed urban/rural discrepancy in 
pertussis incidence has declined, it is still evident. The importance of the commuting 
workforce overall, but especially in counties without interstates, may continue to support 
this theory of delayed pertussis acquisition. The use of immunizations and the increased 
mobility of the U.S. population may mitigate the discrepancy in pertussis incidence rates 
between urban and rural areas.  
The commuting workforce, a variable describing the risk of pathogen introduction, was 
seen to be important both nationally and in counties without interstate highways. This 
variable was selected to address population mixing; however, in counties with an 
interstate highway, county-to-county interactions occur more frequently and for purposes 
beyond employment. So, a single variable quantifying the commuting workforce cannot 
capture the full extent of these interactions. Stratification by region also nullified an 
observed effect of commuting and it is possible that commuting out of county in the 
national model may reflect regional effects, rather than county-level mixing patterns. 




smaller area, when compared to counties in the Midwest and West, where the size of a 
county would limit the proportion of the workforce commuting out of county. 
The only indicator of disadvantage that was a risk factor for increased pertussis in the 
stratified analyses was the proportion of the population with less than nine years of 
education, in the Midwestern states. This change of effect may be result from a 
combination of factors based on the distribution sub-populations in modify the effect of 
what is traditionally identified as a disadvantage and the disease outcome. For example 
individuals in the Midwest are generally characterized as having a strong sense of social 
responsibility. This perspective may result in different cultural perspectives on the 
importance of vaccination, across all levels of society and where vaccine refusers are 
relatively rare, and low vaccination is the result of under vaccination. Both coastal 
regions, the West and Northeast, are more inclined promote individual rights over the 
collective benefit of the community, and have a more heterogeneous mixture of refusers 
and under-vaccinated. However it is possible that in the Midwest the inadequately 
vaccinated are more homogenously under-vaccinated and as a result this variable of low 
educational attainment acts as a proxy for low vaccination levels based on other social 
norms which describe a large proportion of under-vaccination. This may be the case with 
low educational attainment among the Amish, who predominantly reside in the Midwest, 
where low vaccination coverage rates have been reported.
19-22
 These communities are 
supportive of immunizations, though most children have received only some 
vaccinations.
20,21
 This suggests that low education may behave as a proxy for under 
vaccination in this region, and should be interpreted as a cultural barrier to healthcare 
access, rather than an indicator of disadvantage. 
While economic and cultural disadvantage is frequently addressed in populated, urban 
settings, we observed child poverty, crowding, low educational attainment, and a lack of 
medical personnel to have been more prevalent in low density populations. These 
variables were inversely associated with pertussis incidence, as was population density 
itself. Therefore, the counterintuitive directionality of disadvantage being associated with 
lower reported pertussis incidence is consistent across our entire U.S. county sample, not 




result of underreporting based on resource differentials in urban verses rural health 
departments. 
While our analysis was limited to a county-level analysis our findings indicate higher 
disease rates in more affluent counties. The State of Healthcare Quality 2012, published 
using the Healthcare Effectiveness Data and Information Set (HEDIS) reports, show that 
vaccination coverage rates are high among traditionally disadvantaged Medicaid 
enrollees at rates near commercial HMOs and above rates seen in commercial PPOs.
23
 
These higher disease rates in more affluent communities may be a consequence of a 
tendency towards vaccination refusal in white populations with higher education and 
higher income.
24,25
 Regarding disease control, pertussis is observed to occur in both more 
affluent counties and areas of low vaccination. Local public health workers should target 
control measures to these population in incipient outbreak settings.  
This is an ecologic study of disease risk as such our findings describe the risk of pertussis 
at the county level. A study at the county-level is unable to identify the effects of pocket 
populations, who reside within the county. If the sub-population is small then the county 
will generally describe the majority of the population. However if the population is 
divided more evenly the county descriptors will not accurately represent either sub-group. 
This study was also unable to control for vaccination coverage, a strong predictor of 
disease risk and an important descriptor of local healthcare cultural views. 
12
 Low 
vaccination coverage is comprised of two fundamental groups, those who are under 
vaccinated and those who refuse some or all vaccinations. These studies have very 
different demographic profiles. Under vaccination tends to be associated with 
disadvantage, while vaccine refusal is associated with higher education, income and 
maternal age.
12,25
 Our findings are more consistent with the demographic profile of 
vaccine refusal, where affluence is associated with an increased incidence of pertussis.  
These unexpected findings warrant further study, they seem to suggest that the risk of 
pertussis is associated more strongly with vaccine refusal than under vaccination. More 
research characterizing the effects of population density and health care barriers with 
disease specific outcomes will further our understanding of the socio-structural risks 




to better understand the disease risks of their local communities and to develop 








Table 4.10 Initial bivariate analysis of county-level predictors of pertussis incidence 
grouped by risk category bacterial transmission (1), healthcare barriers (2), & poor child 
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*Data from the Census Bureau.  
†
Calculated from ArcGIS roadways map. 






Table 4.2 Summary demographic and socioeconomic measures for United States counties grouped by county rurality (population 
density) and connectivity (presence of an Interstate highway). 
Interstate NO Interstate Interstate NO Interstate 2-Tailed T-test 
   ALL High Density High Density Low Density Low Density Density Interstate 
Variable N=3,143 N= 946 N= 627 N= 422 N= 1,148   
Pertussis Incidence (mean)*  1.88 1.74 1.65 2.15 2.03 < 0.01 0.83 
Age Median (Yrs) 37.32 35.91 36.95 37.47 38.63 < 0.01 < 0.01 
Population Under 5yrs (%) 6.32 6.61 6.30 6.33 6.10 < 0.01 < 0.01 
Children in poverty (%) 17.94 14.71 17.77 19.0 20.31 < 0.01 < 0.01 
Crowding % (1+ person/room) 3.58 3.35 3.09 4.11 3.84 < 0.01 0.93 
Density (persons/sq.mi) 242.87 670.06 161.45 20.08 17.21 < 0.01 < 0.01 
Housing stress (%) 17.12 19.24 15.15 19.67 15.52 0.47 < 0.01 
Interstate miles 17.38 38.74 N/A 42.58 N/A < 0.01  < 0.01 
Low birthweight births % 8.03 8.06 8.17 7.93 7.94 0.02 0.89 
MDs+RNs per 1,000 pop 3.32 7.24 3.20 1.25 0.90 < 0.01 < 0.01 
Racial minority (%) 15.65 17.08 14.08 15.88 15.25 0.44 < 0.01 
Less than High School 
Education (%) 9.09 7.12 9.56 9.52 10.30 < 0.01 < 0.01 
Unemployment (16+yrs) (%) 5.81 5.81 6.40 5.40 5.63 < 0.01 < 0.01 
Uninsured (%) 14.75 12.69 13.61 16.27 16.52 < 0.01 < 0.01 
Workforce Commuting out of 
county (%) 32.62 34.29 35.35 31.08 30.40 < 0.01 0.08 
* Mean, annual, direct age-adjusted cases per 1,000,000 people per year, based on the period 1991-2008. The standard was the U.S. age-









Table 4.11 A negative binomial regression population average model of county-level risk factors associated with reported 
pertussis incidence between 1991 and 2008 in the United States, age stratified. Stratified Models A, separate the data according to 
whether an interstate highway crossed the county borders this is a rough estimate of the inter-county mobility of the population. 
Stratified Models A 
Parameter National  Model Interstate (N=1,368) NO Interstate (N=1,775) 
IRR Conf Int. IRR Conf Int. IRR Conf Int. 
Age Group 
Infant (< 1 yr) 47.19***
 
(44.49 , 50.04) 47.00*** (43.63 , 50.63) 47.8***
 
(43.61 , 52.33) 
Child (1-4 yrs) 6.98*** (6.51 , 7.48) 6.44*** (5.93 , 6.99) 7.52*** (6.75 , 8.37) 
School-aged (5-19 yrs) 5.17*** (4.87 , 5.47) 5.19*** (4.83 , 5.56) 5.09*** (4.66 , 5.56) 
Adult (20 + yrs) 
 
-Reference-   -Reference-   -Reference- 
Crowding (1+ person/room) 1.01 (0.98 , 1.03) 1.00 (0.95 , 1.03) 1.02 (0.99 , 1.05) 
Population Density (Ln) 0.85*** (0.80 , 0.88) 0.84*** (0.78 , 0.89) 0.89** (0.82 , 0.96) 





** (0.96 , 0.99) 0.99 (0.97 , 1.00) 0.96** (0.93 , 0.98) 
Medical personnel (MD& 
RN) per 1000 persons 
1.36
*** (1.20 , 1.53) 1.57*** (1.37 , 1.8) 1.05 (0.81 , 1.35) 
Minorities (%)
†
 0.98 (0.94 , 1.00) 0.96 (0.92 , 1.00) 0.98 (0.93 , 1.02) 





*** (0.76 , 0.93) 0.95 (0.80 , 1.10) 0.79*** (0.7 , 0.89) 
Children in poverty (%)
†
 0.94
* (0.88 , 0.99) 0.96 (0.87 , 1.04) 0.93* (0.86 , 0.99) 
Housing Stress 1.16 (0.98 , 1.37) 1.25* (1.01 , 1.54) 1.07 (0.83 , 1.38) 
Low birthweight infants (%)
†
 0.88
*** (0.83 , 0.92) 0.87*** (0.80 , 0.93) 0.89*** (0.83 , 0.94) 
*
 Significant at  0.05 ≥ p > 0.01 
**
 Significant at  0.01 > p ≥ 0.01 
***
 Significant at p < 0.01 
†
 One increment increase in the percentage measure represents a 5% increase. For example: For every 5% increase in the proportion of the 







Table 4.12 A negative binomial regression population average model of county-level risk factors associated with reported pertussis 
incidence between 1991 - 2008 in the United States, age stratified (continued). Stratified Models B separate counties by U.S. Census 
regions, to determine if there are regional distinctions in pertussis risk factors. 
 
Northeast (N=217) Midwest (N=1,055) West (N=447) South (N=1,424) 
 IRR Conf Int. IRR Conf Int. IRR Conf Int. IRR Conf Int. 
Age Group         
Infant (<1 year) 27.31***
 
(23.36 , 31.9) 40.63*** (36.94 , 44.67) 29.50*** (26.38 , 32.92) 71.60*** (64.59 , 79.36) 
Child (1-4 years) 4.95*** (4.14 , 5.92) 7.10*** (6.40 , 7.87) 5.92*** (5.13 , 6.82) 8.04*** (7.12 , 9.07) 
School-aged (5-19 years) 7.53*** (6.78 , 8.36) 4.94*** (4.53 , 5.37) 3.97*** (3.57 , 4.4) 5.29*** (4.71 , 5.92) 




 -Reference-    -Reference-    -Reference- 
Crowding (1+ person/room) 0.75*** (0.62 , 0.91) 1.02 (0.97 , 1.07) 0.97 (0.93 , 1.01) 1.02 (0.96 , 1.07) 
Population Density(Ln) 0.79**
 
(0.66 , 0.93) 0.93 (0.85 , 1.01) 0.99 (0.91 , 1.06) 0.80***
 
(0.7 , 0.9) 
Commute out of county 
(%)
† 
0.98 (0.93 , 1.02) 1.01 (0.98 , 1.03) 0.98 (0.95 , 1.01) 0.98 (0.94 , 1.01) 
Medical personnel (MD& 
RN) per 1000 persons 
1.36
* 
(1.01 , 1.82) 1.41***
 
(1.19 , 1.64) 1.10 (0.77 , 1.57) 1.18 (0.89 , 1.56) 
Minorities (%)
† 1.14 (0.94 , 1.38) 1.07 (0.99 , 1.14) 1.02 (0.96 , 1.08) 0.98 (0.94 , 1.02) 
Less than high school 
education (%)
† 
0.95 (0.61 , 1.46) 1.20***
 
(1.05 , 1.35) 0.87 (0.72 , 1.05) 0.89 (0.74 , 1.05) 
Children in poverty %
† 1.02 (0.79 , 1.3) 0.91*
 
(0.83 , 0.98) 0.93 (0.84 , 1.01) 0.91 (0.82 , 1.01) 
Housing Stress 1.46 (0.96 , 2.22) 1.03 (0.72 , 1.44) 1.05 (0.82 , 1.32) 0.88 (0.64 , 1.21) 
Low birthweight infants 
(%)
† 
0.82 (0.64 , 1.05) 0.88***
 
(0.82 , 0.94) 1.01 (0.94 , 1.08) 0.90**
 
(0.82 , 0.97) 
*
 Significant at  0.05 ≥ p > 0.01 
**
 Significant at  0.01 > p ≥0.01 
***
 Significant at p < 0.01 
†
One increment increase in the percentage measure represents a 5% increase. For example: For every 5% increase in the proportion of the 
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Chapter 5  
Conclusions 
5.1. Summary of Major Findings and Research Implications 
The introduction of the whole cell pertussis vaccine in the United States during the 1940s 
controlled pertussis transmission to an absolute low in 1976 of 0.46 cases per 100,000. 
The resurgence of pertussis in the United States with the return to widespread, year round  
transmission, and cyclic statewide outbreaks has posed a significant challenge for disease 
control. The addition of booster vaccination in adolescents and adults has not halted the 
increasing baseline incidence of disease. And the cocooning strategy, vaccinating the 
contacts of newborns, has not been effective as only 5% of adults with infant contact had 
received the vaccination.
1
 The incidence of pertussis among infants has also continued to 
increase. The observations of the increasing incidence of pertussis, identification of 
emerging risk groups and vaccination control strategies are based on surveillance data. 
This dissertation (Chapters 2 and 3) evaluates the comprehension of the pertussis clinical 
case definition, based on the secondary data included in the case report. The primary 
finding, presented in Chapter 2, was that only 69.4% of the records could be internally 
validated.  An additional 14.0% reported a cough of insufficient duration to fulfill the 14-
day minimum required of a clinical case. These later cases were termed "suspect," but we 
had high confidence in their diagnosis as valid pertussis cases. These records included 
both a cough attribute (whooping, paroxysms or post-tussive vomiting) and a confirmatory 
indication (PCR positive or epidemiologically linkage), and the average duration of cough 
had an inter-quartile range of 8-12 days. This duration is close to the 14-day minimum 
cough duration required in the clinical case definition for surveillance purposes. At least 
70% of these cases acknowledged incomplete cough data as they were still coughing when 





These findings initiated an additional investigation of the factors associated with reporting 
an inadequate cough duration which fails to meet the clinical case criteria (Chapter 3). 
They also highlighted the incomplete nature of clinical cough length, in surveillance 
records and spurred another investigation of the average complete cough duration of 
illness (Chapter 3).  In that comparison, the average duration of cough was not found to 
differ between those who reported cessation of cough and those still coughing, both 
averaging 25 days (IQR: 15-41 days). Rarely are cases identified by diagnosis tracked for 
the full course of disease. We recognize that an average cough duration of 3.5 weeks is 
quite sufficient for diagnostic and surveillance purposes, though an exhaustive follow-up 
averages 7 weeks and may exceed the resources of the healthcare provider.
2
 Routine 
surveillance data is incomplete regarding reported cough length and should not be used to 
determine the effect of treatment on cough duration. 
When stratified by the first healthcare visit after cough onset, as indicated by the receipt of 
an antibiotic, our findings illustrated an increasing association with the length of the 
reported cough (Chapter 3). The theoretical analysis of case exclusion bias, where 
individuals seeking care in the second week of cough could by definition cough no less 
than 14 days, showed sequentially longer average cough durations when artificially 
truncated over the first 5 weeks of cough. This magnitude of effect from our theoretical 
analysis was observed in the Michigan dataset when stratified by week of cough, 
suggesting that the differences seen in cough duration cannot be attributed to the timing of 
antibiotics.  Surveillance data, in general, is not suitable to determine the average cough 
length or the effect of antibiotics on coughing, as both are predicated on knowledge of a 
complete cohort from disease identification (or exposure) until the cessation of coughing. 
2
 
The 15.6% of cases in the data, who ceased coughing before the end of surveillance, are a 
biased subset who happened to finish coughing within the average follow-up time. They 
are not a representative sample of all cases, because those who reportedly were still 
coughing at the end of surveillance have a similar mean and distribution to those who had 





The suspect cases identified in Chapter 2 failed only this 14-day minimum cough length 
criterion and would otherwise have been reportable confirmed cases. They had sought care 
earlier in the course of illness than those with adequate reported cough durations, as in 
seen in other studies.
3
  Logistic regression analysis of those who sought case prior to 14 
days, associated inadequate cough report with the presence of a confirmatory indication. 
Positive bacterial tests confirmation, both culture and PCR, each had a two-fold greater 
odds of reporting inadequate cough duration. Epidemiologic linkage to a laboratory 
confirmed case increased the odds of inadequate cough duration by a half. These odds 
highlight a misinterpretation of the case definition of the individual assigning the case 
status, probably a health department worker, as a confirmatory indication does not 
supersede the need to fulfill the clinical case definition, except in the case of a positive 
culture, which was obtained in 10.2 % of the cases.  
This excess of incomplete cough duration is most problematic among the PCR-positive 
cases as they comprised 43.0% of the reported cases during the 2000s, and a third of them 
did not include a sufficient cough length. Similar findings of individuals testing positive 
by PCR but having inadequate cough length have been reported.
3,4
An outbreak 
investigation in New Hampshire found that a number of the PCR-identified cases never 
coughed, and some of those who coughed did not have the classic cough attributes 
associated with pertussis. 
4
 When PCR-positive patients present with a cough attribute, it 
should be presumed they are true cases. Our surveillance data was hampered by the high 
proportion of cases still coughing when the surveillance report was finalized. In the 
presence of a cough attribute, other researchers have suggested reducing the minimum 
cough duration to one week.
3
 However, our findings in Chapter 3 suggest that the case 
confirmation criteria are not accurately understood. Therefore, adding an additional 
criterion such as 7-day cough length for PCR cases to the 14-day cough for the clinical 
case definition could be detrimental to the consistency of surveillance reporting.   
The case classification process should be efficient, containing the minimum number of 
criteria to identify highly probably pertussis cases. Based on the analyses in Chapters 2 
and 3, we recommended that cases be defined by the presence of both a cough and cough 




altered, and those identified with an epidemiologic link should continue to be required to 
meet the clinical case definition. High quality pertussis surveillance data is crucial to the 
identification of cases and the commitment of resources in outbreak investigation. They 
are also the basis for vaccination recommendations. 
Chapter 4 evaluated the county-level socio-structural risk factors for pertussis, focusing on 
disease exposure risk, barriers to healthcare and poor child health. We found that pathogen 
exposure risk factors were associated with lower incidence of pertussis. We also 
determined that having a larger proportion of the workforce commuting was a strong 
indicator of decreased risk in counties without an interstate highway. This might be 
attributed to regional differences in county size being inversely correlated with the volume 
of daily population movement into and out of a county. Curiously, barriers to healthcare 
and poor child health were also inversely associated with pertussis incidence. 
Of these barriers, low educational attainment (<9 years) showed a 22% reduction in 
pertussis incidence for each 5% increase in low education within a county, whereas under 
regional stratification an increased risk of pertussis by 20% was seen in the Midwestern 
region. We considered the possibility that education should be interpreted as a proxy for 
healthcare access, as the age-adjusted pertussis incidence was 2.0/100,000 persons greater 
in counties with ≥5% Amish population. The U.S. Amish live primarily in the Midwest 
and adjacent states, and do not continue schooling after the eighth grade. They are also 
known to have low immunization rates, and consequently outbreaks of vaccine 
preventable diseases.
5-7
 It is possible that in the Midwest low educational attainment is a 
proxy for county-level vaccination coverage. 
Some of our healthcare barriers (e.g. physicians per capita, housing stress, children in 
poverty) had been associated with vaccination coverage in a previous study.
8
 However, 
only housing stress correlated with decreased vaccination coverage and increasing 
pertussis incidence. Both a higher per capita prevalence of physicians and less child 
poverty were associated with increased vaccination, but counter-intuitively with increased 
pertussis. This suggests that our findings may reflect more complete reporting in more 






5.2. Challenges Inherent with Pertussis 
Pertussis occurs both seasonally and cyclically with epidemics occurring every 3-4 years 
on average, though this is location specific.
9
 Epidemiologists need to be careful when 
interpreting year-to-year differences both cases and incidence to distinguish between 
cyclic epidemic occurrences and baseline transmission. The Healthy People 2020 goals 
have incorporated these epidemic cycles and now report 4-year averages rather than year-
specific totals.
10
 All analyses in this dissertation collapsed the data over time to create 
averaged the annual pertussis incidences resulting in more robust estimates of disease 
occurrence. 
The highest disease rates occur in infants and adolescents, making it important that 
analyses account for the age distribution of the source population.
11
 Reported pertussis 
rates in different geographic areas should be age adjusted, for comparability.
12 
We used an 
external age adjustment to the 2000 U.S. population when comparing U.S. county-level 
pertussis rates in Chapter 4. The selection of generalized estimating equation models 
allowed us to offset the count of cases by the age-group specific, county population, 
resulting in age-adjusted rates. 
The sporadic nature of disease, and a preponderance of cases in the young, results in low 
case counts among adults, and in counties with sparse populations. This produced 
situations where there were no cases for some county age-groups, in some years. As a 
result we used relatively broad age-groups and collapsed the data across more than a 
decade to help address the over-dispersion (variance greater than the mean) resulting from 
excessive zeros, while using a negative binomial distribution in analyses. This excess of 
zeros could also have been addressed through the use of zero-inflated negative binomial 
(ZINB) regression models. This ZINB analytic method would assess the association 
between predictors, given that a case was reported in a given county. It is based on the 
theory that the initiation of disease, that first case, results from a different process than the 
one that drives the quantity of subsequent cases. For pertussis, this would be true as the 
first cases would be the result of a combination of susceptibility and means of contact with 




5.3. Suggestions for Future Research 
There is growing literature suggesting the reevaluation of the 1997 pertussis surveillance 
case definition. This is usually based on one or more common points of concern:
13
 
1. The reduced sensitivity of the current case definition for infant cases. 
2. The requisite 14-day minimum duration of cough. 
3. The exclusion of serology as a confirmatory disease indicator. 
 
One 2013 recommendation put before the Council of State and Territorial Epidemiologists 
was to include apnea as a clinical indication among infants.
13
 This recommendation is 
based in part on ability of apnea to help differentiate between the frequently similar 
clinical presentations of pertussis and respiratory syncytial virus (RSV) infections. 
Pertussis was noted to have a higher proportion of apnea, cyanosis and lymphocytosis, 
while RSV infections had more frequent fever, vomiting and respiratory distress.
14
 The 
multiple facets of case confirmation are confusing, and while simplicity and continuity 
should be the primary aim of the case definition, further research into the proportion of 
infant cases excluded by the current case definition will help determine the possible 
benefits of refining the case definition by including infant-specific criteria. Current 
estimates suggest 10-20% of infant cases are being excluded.
13
 Many states, including 
Michigan, recognize the importance of apnea, incorporating in the case report form. 
(Appendix) However, more research is necessary to determine its value as part of passive 
surveillance. 
This dissertation was unable to include vaccination coverage in the analysis, primarily 
because nationwide county-level estimates were not available. Vaccination is the primary 
means of prevention and while there was a significant effort to increase vaccination in the 
1990s, many states are lessening the stringency of their exemption policies, either by 
including a philosophical exemption or by reducing the difficulty of gaining an exemption. 
Exemption frequency has been shown to cluster in space, and both frequency and 
clustering are associated with substantial increases in pertussis incidence.
15-17
 Imdad et al., 
showed that even in states where waivers are not easily obtained, religious waivers are 
increasing among public school children.
17
 To better understand pertussis transmission in 
the community setting further work should quantify the cost of these policy changes in 




County-level vaccination rates were not included in analyses presented in this dissertation 
(Chapter 4), due to a lack of standardized nationwide estimates.  Thus, there is the 
possibility that small clusters of low vaccination prevalence may exist within counties. As 
a large proportion of vaccination assessment is done through the public school system, it 
overlooks the populations most inclined to refuse vaccination; those educating their 
children in private schools or at home. Even the National Immunization Survey is not able 
to capture an adequate statistical sample of minority populations within states, particularly 
when the subgroup is not easily classified. As a result, immunization estimates may over-
estimate coverage by failing to detect pockets of high risk which increase the county-wide 
risk of pertussis.
16
 Further study could better elucidate how unvaccinated children who are 
outside the public school system affect accuracy of county-specific vaccination estimates, 
and influence disease outbreaks. 
The study of immunization coverage lends itself well to the inclusion of other socio-
structural investigations. Analyses in Chapter 4 could have been improved with a finer 
spatial resolution of both case occurrences and vaccination coverage. It would be 
beneficial to determine whether the reduced incidence of pertussis observed in Chapter 4 
was the result of lower reporting rates (county resource availability), or lower disease 
occurrence perhaps related to higher vaccination coverage. It would allow state and 
federal public health agencies to more effectively target disease reduction strategies. 
While it is unlikely to be feasible at a national level working closely with a state health 
department should provide sufficient data and expertise to adequately describe the 
interplay between resource availability, vaccination coverage and pertussis. 
Vaccine coverage is the major cornerstone of pertussis prevention, yet the efficacy of the 
vaccine has also recently been drawn into the discussion of pertussis control. The 
observed waning of immune competency within the first five years following vaccination 
by whole cell diphtheria, tetanus and pertussis (DTP)
18
and diphtheria, tetanus, acellular 
pertussis (DTaP)
19-21
 formulations, suggests further research into vaccine efficacy is 
needed. The presence of antigenic-drift in B. pertussis away from the vaccine strains is 
much more problematic for the acellular formulation due to the limited number of 




(FIM), pertactin (PRN), and pertussis toxin (PT) are the virulence factors included in the 
acellular pertussis vaccines.
22
 Some researchers have shown that having initial doses of 
DTP rather than a complete DTaP series provides greater protection in subsequent 
years.
23-25
 Research is needed to determine whether modification to the DTaP components 
can produce a more robust immune response, or whether providing a combination of DTP 
and DTaP, would be most effective for the long-term control of pertussis. This also affects 
the booster vaccination recommendations for adolescents and adults which currently use 
the tetanus, diphtheria, acellular pertussis (Tdap) vaccines.  
The discussion of vaccine formulation would benefit greatly from further research to 
identify additional B. pertussis antigenic components for inclusion in the acellular 
vaccines (beyond the FHA, FIM, PRN and PT that are currently included).
22
 Research on 
the PRN component of the vaccine has shown variants occurring in the Dutch population 
as early as 1980.
26
 This gene product is used in adhering to host tissue and is therefore an 
ideal vaccine target. Within a decade, 90% of B. pertussis isolates were of the newer non-
vaccine strains.
22,26
 This coincides with the resurgence of pertussis and suggests bacterial 
adaptation in response to the whole cell DTP formulation. The shift to the acellular 
vaccine with four basic components can be rendered ineffective by bacterial adaptation 
much more rapidly than the whole cell vaccine. The rate at which each component 
undergoes mutation is important in determining bacterial response to the selective pressure 
of vaccination. This would help determine which vaccine components are likely to have 
reduced effectiveness with time. 
5.4. Conclusion 
The control of vaccine preventable disease like pertussis is an intricate struggle between 
bacteria and humans.  The bacterium B. pertussis struggles for survival to evade the 
human immune system and vaccine-derived immunity. In surveillance data the bacteria is 
noted as a means of diagnosis, though fewer culture tests are being ordered making 
bacterial research more of a challenge. Humankind has developed vaccines as a mean of 
self-protection, though with the decrease of natural infection parental concern has shifted 
to the safety of the vaccines rather than the protection they provide. Vaccination status is 




systems are in place. The effects of both disease and vaccination extend beyond the 
immediate individual affecting their immediate community. The role of surveillance data 
in pertussis control is to provide timely, reliable information regarding affected 
populations, primarily for disease control endeavors. This dissertation highlighted the 
validity of the current surveillance system case definition, though the role of the clinical 
case definition is misunderstood. Surveillance data are a good source of data for further 
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